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ABSTRACT
Background: The molecular adsorbent recirculating system (MARS) is an 
extracorporeal albumin dialysis device that has been used in the treatment 
of liver failure patients to enable native liver regeneration or as a bridging 
treatment to liver transplantation (Ltx). MARS treatment was first used in 
Finland in 2001, and since then, over 200 patients have been treated. 
So far, small randomized controlled trials and numerous case series have 
shown the favorable effects of the MARS treatment on surrogate markers. 
However, adequate data are still lacking on the possible survival benefit 
offered by the MARS treatment when compared to the standard conservative 
medical therapy.
Aims: The aim of this thesis is to evaluate the impact of the MARS treatment 
on the patient outcome, clinical and biochemical variables as well as the 
psychological and economic aspects of the treatment for the different types 
of liver failure patients in Finland. 
Patients and methods: This thesis encompasses 195 MARS-treated patients 
including patients who had acute liver failure (ALF), acute-on-chronic liver 
failure (AOCLF) and graft failure, and a historical control group of 46 ALF 
patients who did not undergo the MARS treatment. All patients received 
similar standard medical therapy at the same liver-disease specialized 
intensive care unit in Helsinki. The baseline demographics, biochemical 
laboratory parameters, and clinical variables as well as the MARS treatment-
related and health-related quality of life data were recorded before and after 
the MARS treatment. The direct medical costs, which incurred during a 
time period of 3.5 years, were determined. The outcome was determined for 
patients including their survival, native liver recovery rate and their need 
for Ltx. Additionally, survival predicting factors were investigated in each 
liver failure etiological subgroup. 
Results: In the outcome analysis, the 6-month survival was higher for the 
MARS-treated ALF patients as compared to the historical control group 
(75% vs. 61%, P=0.07), and rate of native liver recovery was higher (49% 
vs. 17%, P<0.001) and the need for Ltx was lower (29% vs. 57%, P= 0.001), 
respectively. However, the etiological distribution of the ALF patients 
referred to our unit has changed considerably over the past decade and the 
percentage of patients with a more favorable prognosis (e.g. toxic etiology) 
has increased. The etiology of liver failure was the most important predictor 
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of the outcome (P<0.0001). Other survival predicting factors included the 
grade of the hepatic encephalopathy, the plasma concentration of coagulation 
factors and the liver enzyme levels prior to MARS treatment in ALF patients. 
In terms of prognosis, the MARS treatment of the cirrhotic AOCLF patients 
does not seem meaningful unless the patient is eligible for Ltx. 
From the clinical and biochemical viewpoint, the MARS treatment 
appears to reduce or halt the progression of encephalopathy in all the liver 
failure etiologies. Moreover, the MARS treatment reduced significantly the 
plasma concentration of most neuroactive amino acids and other albumin-
bound (e.g. bilirubin) and water-soluble toxins (e.g. creatinine and urea). 
The MARS treatment effects seem to stabilize the patients, thus allowing 
additional time either for the native liver to recover and to regenerate, or 
for the patient to endure the prolonged waiting for an Ltx.
From the perspective of the economics and the health-related quality 
of life, in the cost utility analysis, the MARS treatment appeared to be less 
costly and more cost-efficient than the standard medical therapy alone in 
ALF patients because it reduced the need for Ltx. 
Conclusions: The MARS treatment appears to have a beneficial impact on the 
outcome of ALF patients and those AOCLF patients who can be bridged to 
Ltx. On the other hand, the AOCLF patients with end-stage cirrhosis who 
are not eligible for Ltx have an extremely poor prognosis and do not seem 
to benefit from MARS treatment. 
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INTRODUCTION
In liver failure, the impairment of the normal metabolic, synthetic and 
detoxification function of the liver cells leads to the accumulation of various 
toxins. Currently, this toxin overload is considered to be the main cause of 
the patophysiological signs and of the end-organ damage in liver failure 
patients[319, 339]. Some of these toxins are water-soluble (e.g. ammonia, 
lactate and urea) and can be removed by conventional hemodialysis or 
hemofiltration. However, a substantial part of the endogenous toxins (such 
as bilirubin, bile acids and aromatic amino acids) are albumin-bound in the 
blood and cannot be removed with dialysis. 
The molecular adsorbent recirculating system (MARS) machine was first 
introduced in the 1990s as a novel extracorporeal treatment modality for 
liver failure patients[336-339]. The main goal of the MARS albumin dialysis is 
to remove both endo- and exogenous water-soluble and albumin-bound 
toxins from the patient’s blood, and thereby compensate for the loss of 
the detoxification function of the liver. In liver failure patients, the MARS 
treatment has been used to sustain vital organ functions either to facilitate 
native liver recovery or as a bridging treatment to liver transplantation (Ltx) 
until a suitable organ is found.
The effect of the MARS treatment on the clinical variables and on the 
outcome of patients has been investigated in a wide range of  liver failure 
etiologies with promising results[54, 69, 95, 145, 248, 354, 366]. Only a few small case 
series have been published that have concentrated solely on acute liver failure 
(ALF) patients[69, 190, 200, 393]. Mostly ALF patients have been reported in studies 
as a small subgroup within other indications[54, 245, 340, 344, 387]. The impact of 
the MARS treatment on surrogate markers such as laboratory variables, 
toxin removal capacity and the effect on clinical variables (encephalopathy, 
hemodynamic profile, etc.) have also been the focus of extensive research[54, 
191, 231, 232, 313, 344, 388].    
Despite numerous studies of the MARS treatment in liver failure 
patients, conclusive evidence is still lacking on its beneficial effect on patient 
outcome[176]. In fact, only eight small randomized controlled trials (RCTs) 
have been published on the MARS treatment containing mainly chronic 
liver failure patients[95, 138, 141, 191, 231, 320, 333, 335].  
In Finland, the MARS treatments were initiated in May of 2001 at the 
liver-disease specialized intensive care unit (ICU) and Ltx center at the 
Helsinki University Central Hospital (HUCH) and currently over 200 
patients have been treated. Nevertheless, few uncontrolled case series have 
been published on the outcome of the very first MARS-treated patients in 
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Finland[180, 181, 189]. These studies concluded that the MARS treatment seems to 
be a promising new therapy especially for ALF patients. However, usefulness 
of this treatment was questioned for chronic liver failure patients who were 
not eligible for Ltx[181]. In light of these encouraging preliminary results, 
further  studies were planned.  
There are a number of commonly recognized problems in designing 
studies to evaluate the efficiency of liver assist devices[33]. The first challenge 
is that there is a great variation in etiology and severity of liver failure 
from country to country and this has a substantial impact on the prognosis 
of the patients[202, 252, 258]. The second problem is that due to the absence 
of the well-recognized guidelines for the initiation and duration of the 
MARS treatment, the different centers have their own inclusion criterion 
and treatment schedules. Thirdly, the availability and waiting time for Ltx 
differ substantially worldwide, and in some countries, cadaveric donor 
organs are virtually non-existent. All of the abovementioned factors make 
it difficult to compare results from different centers and studies. In addition, 
the low incidence and high mortality in ALF and graft failure (GF) make it 
challenging to enroll large number of patients for any study[204].  
The aim of this thesis was to investigate the multiple aspects of the MARS 
treatment with long follow-up periods to better understand the mechanisms 
of treatment effects and to evaluate which patients most benefit from the 
MARS therapy. 
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REVIEw OF THE LITERATURE
FUnCTIons oF THe HeALTHY LIVeR
The liver is the largest organ in the human body weighing approximately 
1.5 kg in a healthy adult. The liver receives its blood flow through two 
systems, the portal vein and the hepatic artery. Together these vessels carry 
approximately one-third of the cardiac output. The portal vein brings venous 
blood from the small and large intestines and pancreas to the liver so that 
the nutrients and other substances adsorbed from the gastrointestinal (GI) 
tract come into contact with hepatocytes through large fenestrations in the 
liver endothelium. The hepatic artery, carrying oxygenated blood, provides 
only one-fifth of the entire blood flow to liver (Figure 1.).
Figure 1. Anatomy of the liver 
Inferior vena cavaRight lobe
Hepatic artery
Portal vein
Common bile duct
Inferior vena cava
Gall bladder
Left lobe
Falciform ligament
The liver has a wide range of complex functions, which are listed in Table 1. 
A complete loss of hepatic function leads to irreversible multi-organ failure 
and inevitable death, usually within 48 hours. However, unlike most other 
organs in the human body, the liver has a remarkable capacity to regenerate 
after an insult, as has already been noted in the 1960s[206]. This unique quality 
of the liver was even recognized by the ancient Greeks and depicted in the 
legend of Prometheus. 
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Table 1. Various functions of the healthy liver
Metabolism & Synthesis
Proteins 
Amino acid and nitrogen metabolism  
(ammonia production through nucleic acid and protein metabolism)
Production of plasma proteins (50g/day)  
(e.g, transferrin, ceruloplasmin, albumin, C-reactive protein, lipoproteins)
Production of coagulation factors  
(fibrinogen, prothrombin, factors V, VII, IX, X,XI and XII, protein S and C and antithrombin III)
Production of hormones  
(e.g. Insulin-like growth factor, Angiotensinogen) 
Carbohydrates 
Glucogenesis  
(synthesis of glucose from amino acids alanine and glutamine, lactate and glycerol)
Glycogenesis  
(production of glycogen from glucose)
Glycogenolysis  
(conversion of storage glycogen to glucose)
Metabolism of galactose and fructose
Lipids
Synthesis and degradation of cholestrol, fatty acids and lipoproteins
Lipogenesis  
(synthesis of triglyserides)
Ketogenesis  
(production of ketone bodies from fatty acids)
Bile formation and excretion (~600ml/day) 
Urea synthesis from ammonia 
Breakdown and Detoxification
Breakdown of many hormones and hemoglobin
Metabolism and detoxification of endo- and exogenous toxins and drugs
Storage
Glycogen, various vitamins (e.g. A, D, B12), copper, iron, blood reservoir
Immunology
Via the active reticuloendothelial system
Production of the complement system factors
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LIVeR FAILURe
In a clinical setting, liver failure can be divided into three main categories, 
depending on the mechanism by which the damage occurs: acute liver failure 
(ALF), acute exacerbation of chronic liver disease i.e. acute-on-chronic liver 
failure (AOCLF) and liver graft failure (GF) after an Ltx[25]. The distinctive 
features of all the main liver failure categories will be discussed separately 
in the following chapters.
ACUTe LIVeR FAILURe
definitions 
The first definition of ALF in the 1970s was based on the presence of 
coagulopathy and the development of an altered mental status (e.g. hepatic 
encephalopathy (HE)) within 8 weeks of the onset of the first symptoms in 
a person with no previous history of liver disease[359]. The term “late onset 
hepatic failure” was used to describe a group of similar patients in whom 
this interval ranged from nine to 26 weeks[359]. Since then, the definition of 
ALF has been challenged and redefined by many[37, 38, 128, 253]. For example, 
Bernuau et al. first proposed the term fulminant hepatic failure (FHF) to 
encompass a subgroup of patients who developed HE within 2 weeks of the 
onset of jaundice[37]. Another subgroup of patients with a more insidious 
onset of disease and a delayed presentation of HE (up to 8 to 12 weeks) were 
classified as having subfulminant hepatic failure (SFHF)[37].
Another classification system for ALF was suggested in 1993 by John 
O’Grady[253]. In this system, liver failure is also classified according to the 
time, which elapses from jaundice to HE, which is 1 week in hyperacute 
liver failure, 8-28 days in acute liver failure and 4-12 weeks in subacute liver 
failure[253]. 
Young children with ALF may not develop HE until very late. As a 
consequence, it is widely accepted that HE is not essential in the diagnosis 
of ALF in children[39, 86]. Currently, the general definition of ALF in adults has 
also encompassed patients who have not yet developed HE despite rapidly 
failing liver function (increasing liver enzyme and bilirubin levels and/or 
decreasing coagulation factor levels) without previous liver disease[47, 101, 107, 
382].  
incidence
ALF is a rare condition[204]. Moreover, a multitude of liver diseases can cause 
ALF and their relative frequency varies throughout the world[202]. Throughout 
the world, including Finland, the exact numbers of the incidence of ALF are 
missing mainly because the ICD-10 classification does not include specific 
codes for ALF. Therefore, a precise assessment of morbidity or mortality 
due to ALF in our country is not possible. According to the Finnish liver 
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transplantation registry (FLTR) during 2000-2008, 6-10 ALF patients were 
transplanted each year. The national numbers of the treated ALF patients are 
not available due to the lack of studies. In the United States, the  incidence 
of ALF has been estimated at 0.7 patients/100 000 inhabitants/year. Today, 
numbers are available from the U.S. Acute Liver Failure Study Group, which 
was formed in 1997 as a consortium of tertiary liver units, and this group 
estimates that 2,800 new ALF cases occur per year[178].
Patophysiology and cellular mechanisms 
of hepatocyte and liver damage 
The mechanisms of liver failure and liver cell (i.e. hepatocyte) damage has 
been studied mainly in in-vivo models because the hepatocytes in the in-
vitro experiments do not remain viable and differentiated for long periods 
of time[183, 293]. 
It is believed that in ALF, the primary insult to the hepatocytes is caused 
by a noxious stimulus (e.g. virus, drug, and ischemia) and followed by 
a secondary injury induced by the release of proinflammatory cytokines 
(e.g. interleukin-1, interleukin-6 and the tumor necrosis factor alpha) and 
cytotoxic mediators from the damaged liver cells. The subsequent neutrophil 
migration to the liver tissue results in the discharge of free oxygen radicals 
and proteinases, causing a breakdown of the cell membranes and organelles. 
These cascades finally trigger apoptotic pathways which then cause cell death 
and on a larger scale, liver necrosis[120, 217, 259]. 
The impairment of normal metabolic and the detoxification function 
of the liver cells leads to the accumulation of various albumin-bound and 
water-soluble toxins (bilirubin, ammonia, lactate, bile acids, aromatic amino 
acids, fatty acids, mercaptans, phenols and endogenous benzodiazepines) 
[319, 339]. As the concentration of accumulating albumin-bound toxins exceeds 
the critical binding capacity of the albumin molecule, the free fraction of 
the toxins in plasma begins to rise, causing direct damage to the different 
organ systems. Thus, the accumulation of toxic metabolites is considered 
to be the main cause of the patophysiological signs and end-organ damage 
in liver failure[319, 339]. In fact, studies have shown an increased activation of 
the pro-apoptotic pathways when plasma from the patients suffering from 
ALF of AOCLF has been added to the human hepatocyte cultures[225, 297]. 
The injury of the endothelial cells of the liver causes impairment in 
microcirculation, perfusion and oxygen delivery, resulting in further tissue 
hypoxia. As the detoxification capacity of the hepatocytes is lowered, 
the circulating endotoxins induce the remaining cells to produce more 
vasoconstrictor and proinflammatory mediators, thus perpetuating the 
vicious circle of further cell injury[288].  
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clinical characteristics
In clinical practice, the prodromal symptoms of ALF (fatigue, fever, nausea 
and abdominal pain) are usually very ambiguous and develop gradually over 
days or weeks. ALF is characterized by the development of jaundice, altered 
mental status, coagulopathy, susceptibility to infection[282, 285], acid-base and 
electrolyte imbalance[385], renal failure[279], hypoglycemia and hemodynamic 
instability[96]. Furthermore, once the clinical condition begins to deteriorate, 
and especially when HE sets in, the patient should be transferred to an ICU. 
The rationale for this is the characteristically rapid worsening of HE and 
the development of multiple organ damage, which might prevent future 
transportation to a liver ICU, and an Ltx center[204, 270].   
The leading causes of death in ALF are brain edema, leading to tentorial 
herniation, an uncontrollable septic infection and irreversible multi-organ 
failure [107, 258, 352]. In many patients, all of the aforementioned complications 
are present at the time of death. A summary of the effected organs in ALF 
are presented in Figure 2.
Figure 2. Effected organs and metabolic derangements in acute liver failure
etiology
ALF can be caused by a heterogeneous range of noxious agents, which 
are summarized in Table 2. The etiology of liver failure is one of the most 
important factors determining the prognosis of the patient with ALF[202, 252, 258]. 
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For this reason, when ALF is suspected, a thorough and rapid investigation 
of all causative agents should be carried out[204]. 
Table 2. Etiologies of acute liver failure
The etiological distribution of causative agents in ALF varies markedly with 
geography[149, 202, 203]. In the North America and some European countries, 
toxic etiology is the most common cause of ALF[204, 255, 258] as opposed to 
many Southern European and developing countries, as well as Japan, where 
a viral origin is dominant[5]. During the past decades, a shift has occurred 
towards the more benign etiologies of ALF such as paracetamol-intoxications 
resulting in higher overall survival and native liver recovery rates[31, 175, 198, 
203, 204].
Etiologies of acute liver failure
VIRAL
hepatitis viruses A, B, C, D and E
other viruses varicella zoster, adeno, yellow fever, cytomegalo, 
human herpes virus 1 & 2, Epstein Barr
TOXIC
Drug-induced
dose-dependent Paracetamol, salicylates, iron
idiocyncratic Valproate, tuberculosis medicines, nimesulide, allopurinol, statins, 
disulfiram, azatioprin 
Ketokonazole,sulfonamides, quinolones, methyl-dopa,  
anabolic steroids, phenytoin
synergistic Alcohol + paracetamol, amoxicillin+clavulanate, 
isoniatzid+rifampizine, trimethoprim + sulfamethoxazole
Poison Tetrahydrochloride, chlorobenzenes, yellow phosphorus, cocaine, extacy
Toxin Amanita phalloides, many herbal products  
(Chaparral, Chelidonium majus)
VASCULAR Budd-Chiari  syndrome
PREGNANCY Fatty liver of pregnancy, HELLP-syndrome
SYSTEMIC
Copper  metabolism Wilson’s disease
Autoimmune Autoimmune hepatitis
OTHER
Malignancies Malignant infiltration (lymphoma/acute myeloid leukemia)
Trauma
Cardiovascular Shock liver due to ischemia (resuscitation, acute 
myocardial infarction, cardiac tamponade)
Heatshock
Infection Sepsis
UNKNOWN No definable cause can be found in extensive investigations
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Worldwide, the most common cause of ALF is an infection caused by 
a hepatitis virus. Only 0.2-4% of the hepatitis virus infections progress to 
ALF, and even in the high endemic areas (Africa, Asia and South-America), 
viral hepatitis tends to have a chronic clinical course[255]. The most common 
viral etiology of ALF are hepatitis virus B, A and E. Hepatitis virus E is 
most commonly seen in the developing countries, pregnant women and in 
immuno-compromised patients[9]. However, hepatitis virus C rarely causes 
ALF [149, 255]. In Finland and other Scandinavian countries, hepatitis virus 
induced ALF is rare and therefore, is hardly ever the indication for an Ltx [47].
In toxic drug-induced ALF, liver damage can occur in a dose-dependent 
manner if the drug has a narrow therapeutic range (e.g. paracetamol). ALF 
can also develop as an immunologically mediated idiosyncratic reaction, 
which usually takes place within the first 4-6 weeks of the initiation of a new 
treatment (e.g. isoniatzid/rifampicin, azatioprin)[126]. The list of potentially 
hepatotoxic drugs is long but the most common drug triggering ALF in the 
developed countries is the suicidal ingestion or unintentional overdose of 
paracetamol[31, 202, 204]. In addition to drugs, various exogenous toxins and 
herbal products can also cause ALF[242] (Table 1).
Paracetamol-intoxication occurs when the liver’s metabolizing capacity is 
saturated, when the glutathione stores are depleted and when the cumulating 
toxic metabolite (N-acetyl-p-bentzoquinoneimine) of paracetamol causes 
hepatocyte necrosis and renal tubular damage[217, 271]. Usually  the single-
dose of paracetamol required to cause ALF is over 12g/day but much 
lower quantities have been reported to cause toxicity[215] especially if used 
continuously and by patients with altered metabolic states[74, 254, 258]. The 
factors, which can facilitate the development of drug-induced hepatotoxicity, 
include malnutrition, very young or old age, impaired renal function, 
simultaneous intake of P-450 cytochrome inducing drugs, alcohol or other 
hepatotoxic substances[44, 254, 379].  
Amanita phalloides mushroom intoxications and the pharmacokinetics 
of the amatoxins have been studied in both human poisoning patients and 
dogs[108, 159, 372]. Here the ingestion of even a single full-grown mushroom 
can lead to ALF with a high associated mortality without treatment[99]. The 
amatoxins are rapidly adsorbed from the GI tract and quickly disappear 
from the blood stream as they enter hepatocytes and bind to the cellular 
RNA-polymerase II. While the exact molecular cascades which lead to 
cell death are not fully understood, it is known that amatoxins, such as 
the alpha-amanitin, inhibit protein synthesis in the affected cells[372]. The 
amatoxins taken-up by the hepatocytes are then excreted into the bile and 
subsequently reabsorbed from the GI tract, constituting an enterohepatic 
cycle. Approximately 90% of the ingested amatoxins are excreted via urine 
unmetabolized[99]. In fact, due to this rapid distribution into other body 
compartments, the reported plasma half-life of amatoxins is 37-50 min in 
dogs[108]. In human studies, amatoxins are rarely detected in plasma 36h 
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after intoxication[159]. Therefore, serious Amanita poisoning can occur even 
if serum samples taken 24h after the mushroom ingestion do not show 
detectable levels of amatoxin[168, 171].  
The diagnosis of unknown or indeterminate etiology ALF can be 
established only after a thorough examination and exclusion of the known 
causes. The percentage of ALF patients having indeterminate etiology has 
been reported at 17% in the U.S.[258], 27% in Canada[352], 32% in Spain and 
France[42, 101] and 62% in India [5]. In a Scandinavian study, a large portion 
of the transplanted ALF patients (~40%) had an unknown etiology of 
ALF[47]. According to the most recent statistics from FLTR (1982-2009), 
62% (90/147) of all the transplanted ALF patients had an unknown etiology. 
current conservative management of acute liver failure 
The rarity and great variance in etiology and severity of ALF make it difficult 
to compare treatments or to carry out sufficiently powered studies. For 
the same reason, although general management guidelines have been 
recommended, the standardized intensive care treatment protocols for ALF 
have not been established [34, 270, 347].
The treatment of ALF aims at preventing the development of complications 
and irreversible organ damage (such as brain herniation) while waiting 
for native liver regeneration or for a suitable liver graft for an Ltx[34, 166, 
270, 347]. The first line of treatment for ALF entails conservative medical 
and pharmacological management in an ICU setting. The next step, if 
conservative treatment fails to improve the clinical condition of the patient, 
is to use liver-assist devices (e.g. MARS). Finally, if native liver recovery is 
not expected,  an Ltx remains the treatment of choice[32, 204].  
The standard medical therapy (SMT) usually starts with an extensive 
evaluation of the origin and severity of ALF[34] (Table 3.). The potentially 
rapid progression of ALF necessitates an early consultation of the nearest 
transplant center. Furthermore, a patient exhibiting  any signs of mental 
abnormality should be immediately transferred to the nearest Ltx center and 
have the suitability for an Ltx evaluated[204, 270]. The next chapters describe in 
detail the SMT of the ALF patients treated in an ICU setting.
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Table 3. Investigations required to establish the etiology of the 
acute liver failure and clinical follow-up of the patient 
The preliminary investigations in acute liver failure
ETIOLOGY OF LIVER DISEASE
Medical history (if the patient is incapacitated, family members/friends will be asked)
onset of symptoms, family history of liver disease
Risk behavior
blood transfusions, sexual contacts, body piercings/tattoos, occupation, travel history
ingestion of alcohol/illicit drugs/anabolic steroids/
medication/herbal products/mushrooms
Specific etiology
viral etiology: viral hepatitis serology
systemic disease: Ceruloplasmine, urine copper
autoimmune markers: antinuclear and smooth muscle antibodies
toxic  screens: paracetamol levels, blood/urine toxicology and drug screen
Radiological and histological diagnosis
Abdominal doppler-ultrasound, computerized 
tomography and liver biopsy when necessary
CLINICAL FOLLOW-UP & MONITORING
vital signs
assessment of mental status (transcranial doppler ultasound and EEG if  necessary)
signs of jaundice, ascites, bruising, bleeding and size of the liver
cardiovascular status (EKG and invasive blood pressure monitoring)
chest x-ray
urine output and presence of edema
LABORATORY INVESTIGATIONS, SEVERITY OF THE DISEASE
liver cell damage: liver transaminases (ALT, AST)
cholestasis: bilirubin, alkaline phosphatase,  γ-glutamyl transpeptidase (GGT)
coagulation status: coagulation factor panel (INR, factor V)
synthetic capacity of the liver:  albumin, prealbumin
kidney function: creatinine, urea, cystatin-c
general: complete blood count, blood type
infection parameters: C-reactive protein
metabolic state; Na, K, Ca-ion, acid-base balance, lactate, ammonia
glucose metabolism: blood glucose
liver function tests: galactose T½, indocyanine green, etc.
Monitoring in the ICU
Basic monitoring includes the EKG, arterial and central venous blood 
pressure, pulseoxymetry and urinary output measurement. In the 
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encephalopathic patients, the cerebral blood flow velocity can be estimated 
by using the transcranial-doppler ultrasound[10, 41]. It is important to note 
that invasive intracranial pressure monitoring devices are no longer used 
in many ICUs due to the risk of bleeding complications[45, 369]. Moreover, 
the use of these devices has not been shown to increase survival[369]. In a 
hemodynamically unstable patient requiring massive inotropic support, 
pulmonary artery cathetrization should be considered[270]. The nasogastric 
tube is also used for enteral nutrition in patients with altered mental status.
Hemodynamics
The hemodynamic instability in ALF is characterized by hyperdynamic 
circulation with high cardiac output, low vascular resistance and low mean 
arterial pressure (MAP). During the initial stages of ALF, vasodilatation 
is usually generalized and may respond to fluid replacement therapy. 
Later, through the activation of the neurohumoral system, vasodilatation 
is regionalized to peripheral and splanchnic vascular beds, which also 
become hyporesponsive to vasoconstrictive stimuli. The resulting relative 
hypovolemia and renal vasoconstriction cause lowered renal perfusion 
pressure[166]. It has been speculated that these abnormalities are due to the 
high concentration of circulating endotoxins and vasodilatory substances 
such as nitric oxide, which are normally removed by the healthy liver[126]. 
Relative adrenal insufficiency has also been suggested as one of the possible 
factors causing cardiovascular collapse in ALF patients[136].
The most commonly used vasoactive agent to maintain adequate MAP 
is noradrenalin infusion[34, 347]. Terlipressin, a vasopressin analog, has also 
been investigated but is not currently recommended because it seems to 
increase the intracranial pressure (ICP) in ALF patients[324, 347].
Hepatic encephalopathy, brain edema and neuroactive amino acids 
One of the hallmark features of ALF is HE. It is defined as a potentially 
reversible neuropsychiatric disorder presenting as a decreased level of 
consciousness associated with liver failure[67, 111]. Although a direct positive 
correlation between the grade of HE and ICP has not been established, one 
study showed that approximately 80% of the ALF patients with a grade 4 HE 
also had significant cerebral edema[94]. Furthermore, the presence of brain 
edema is usually more common in hyperacute, fulminant, and in acute forms 
of ALF than in the subacute type[37, 253].  
The correct management of HE and brain edema is extremely important 
because one of the leading causes of death in ALF is brain herniation resulting 
from increased ICP[258, 352]. For this reason, the mental status of each liver 
failure patient should be closely monitored by using the West-Haven criteria 
(Table 4.)[67, 111]. 
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Table  4. The grading of hepatic encephalopathy 
according to the West-Haven Criteria
Encephalopathy grade Mental status & clinical signs
0 Normal
1 Shortened attention span, anxiety or euphoria, drowsiness
2 Lethargy, personality changes, disorientation of 
space and time, slurred speech, hyperreflexia
3 Confusion, gross disorientation and bizarre 
behavior, still responsive to verbal stimuli
4 Unconscious, may be  unresponsive or respond 
to strong painful stimuli, comatose
Patophysiological mechanisms causing hepatic encephalopathy
The patophysiological mechanisms causing HE and brain edema are likely to 
be multifactorial. According to current knowledge, HE is believed to result 
from the accumulation of various endotoxins in the brain tissue, causing 
a loss of autoregulation and impairing oxygen and glucose metabolism. 
Other possible mechanisms explaining the pathogenesis of HE have also 
been proposed, such as the development of false neurotransmitters, release 
of inflammatory mediators and oxygen radicals and imbalance in the ratios 
of plasma and intracerebral amino acids[112, 139, 323, 370].
In healthy humans, cerebral blood flow is tightly autoregulated and 
maintained to be constant through a wide range of systemic blood pressure 
variation (MAP 60-150mmHg) [263]. In ALF, the encephalopathic patients 
have lost this autoregulatory mechanism and their cerebral blood flow is 
directly proportional to their systemic blood pressure[82, 194]. Therefore, it is 
important to  monitor and maintain normal MAP (~ 60-80mmHg) in these 
patients to prevent them from developing either hypo- or hyperperfusion 
of the brain. The consequences of brain hypo- or hyperperfusion are brain 
ischemia or hyperemia, respectively. Hyperemia of the brain results in 
intracranial hypertension and decreased cerebral perfusion pressure. This 
cascade eventually leads to further impairment of the brain cell metabolism, 
to tissue swelling and finally to herniation[165].
In the development of HE, the role of the plasma amino acids, among 
other neurotoxic substances, has been recognized from the 1970s[110, 113]. It has 
been hypothesized that the dysbalance between the excitatory and inhibitory 
amino acids  might play a central role in the development of HE[52, 53, 209, 313]. 
As noted by Fischer et al., liver failure patients tend to have an increased 
plasma concentration of tryptophan, tyrosine, and phenylalanine, which 
are aromatic amino acids (AAAs). In contrast, the concentration of valine, 
isoleucine and leucine, which are branched chain amino acids (BCAAs), is 
reduced. This characteristic amino acid dysbalance results in a low Fischer’s 
ratio, which is defined as the ratio between the BCAAs and the AAAs[113]. 
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It has been speculated that in liver failure patients, the low levels of the 
BCAAs result in a decreased production of excitatory neurotransmitters, and 
the high levels of the AAAs increase inhibitory neurotransmitter production. 
In addition, encephalopathic patients have been shown to have increased 
levels of the amino acid methionine, which is a neurotoxic substance 
released into the blood stream during liver necrosis[147]. The increased plasma 
concentration of other neuroinhibitory or neurotoxic substances, such as 
endogenous benzodiazepines, manganese, copper, phenols, mercaptans, 
pro-inflammatory cytokines and bilirubin, might also play a part in the 
pathogenesis of HE[53, 209]. 
The ammonia-glutamine theory proposes that an increased concentration 
of arterial ammonia  causes disturbances in the re-uptake of glutamate 
and in the metabolism of glutamine in the brain[243, 323]. In liver failure, the 
detoxification of ammonia is impaired and the astrocytes in the brain act 
as an alternative metabolic pathway to convert the excess ammonia and 
glutamate into the amino acid glutamine[220, 323]. Accumulating glutamine 
then acts as an organic osmolyte, favoring the movement of water into the 
brain tissue and thus, causing astrocyte swelling. In addition, high ammonia 
concentration has a direct toxic effect on the nervous system[323]. To support 
this theory, a recently published study demonstrated a correlation between 
brain glutamine, arterial hyper-ammonemia and increased ICP in human 
subjects with ALF[355]. Another cause for the swelling of the brain tissue might 
be the loss of cerebral autoregulation, resulting in an increased cerebral blood 
flow and blood volume[194, 197]. Regardless of the original cause, the swelling 
of the astrocytes causes brain edema. Due to the limited space within the 
bony skull, brain edema results in increased ICP, which can lead to tentorial 
herniation and death[355]. 
There is also evidence supporting the “toxic liver” hypothesis that toxic 
substances released from the necrotic liver cause an increase in the ICP. This 
theory is supported by the clinical observations that ICP usually normalizes 
during the anhepatic phase of an Ltx[83, 161].
In summary, the various patophysiological mechanisms causing HE 
in liver failure patients include the dysbalance between the BCAAs and 
the AAAs[52, 53, 209, 313], the elevated levels of other neuroinhibitory and the 
neurotoxic amino acids and other substances[53, 113, 147, 209], the abnormal 
ammonia-glutamate metabolism[165, 243, 323] and the loss of cerebral blood 
flow autoregulation[194, 197].
Management of hepatic encephalopathy
The medical management of HE and brain edema aim at maintaining the 
ICP below 20mmHg and the mean cerebral perfusion pressure (=MAP-ICP) 
between 50-70mmHg[34, 347]. The avoidance and correction of any factor 
which might increase ICP, such as hypo- or hyperglycemia, fever, hypoxia, 
hypercapnia and electrolyte imbalance, is essential[68, 165, 239]. Furthermore, 
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environmental stimuli should be kept to a minimum and the patient should 
be adequately medicated before any procedure[239]. 
All sedative medication should be discontinued in non-intubated patients 
in order to adequately assess their level of consciousness. According to recent 
guidelines, if the grade of HE reaches three or four, the patient should be 
sedated, intubated and mechanically ventilated to prevent hypercarbia, 
hypoxia, and aspiration[34, 347]. In intubated patients, adequate sedation should 
be administered to prevent the patient from coughing or straining against 
mechanical ventilation[270]. Whereas hyperventilation has been shown to 
reduce ICP, this effect is usually temporary. Therefore, hyperventilation is 
only used, if life-threatening ICP emergency is suspected[94]. 
The pharmacological management of brain edema aims at reducing 
ammonia production (synthesized mainly by gut bacteria). Bowel 
decontaminating antibiotics (e.g. ciprofloxacin) and lactulose (which acts 
as a prokinetic inhibiting the overgrowth of GI bacteria) have been used 
to reduce ammonia production and the incidence of brain edema[13, 24]. In 
refractory intracranial pressure emergencies mannitol[55], hypertonic sodium 
chloride-infusion[240], phenytoin, temporary hyperventilation[94], propofol[384], 
moderate hypothermia (32-33°C)[160, 161, 164], thiopental-infusions[117], and 
even hepatectomy[289] have been used as a last resort to decrease ICP and to 
reduce brain edema.
Renal failure and the hepatorenal syndrome
Renal dysfunction or failure occurs in 30-70% of the ALF patients[258, 279]. 
Renal failure is particularly common in the paracetamol intoxications due to 
the direct toxic effect of the paracetamol metabolites causing acute tubular 
necrosis[44, 71].
Hepatorenal syndrome (HRS) refers to a reversible functional renal 
impairment that occurs mostly in advanced cirrhosis but also in ALF 
patients. Type 1 HRS is defined as the doubling of serum creatinine or 
reduction in creatinine clearance in less than two weeks in a patient with 
liver failure.  In addition, all other possible causes for post- and prerenal 
renal failure have to be ruled out and fluid replacement and withdrawal of 
the nephrotoxic drugs does not improve renal function[16]. 
The cause of HRS is as of yet unknown but various theories about 
the underlying patophysiological mechanism have been proposed. For 
instance, the peripheral vasodilatation hypothesis suggests that type 1 
HRS and functional renal failure are caused by the vasodilatation of the 
splanchnic and peripheral capillary beds leading to relative hypovolemia, 
renal vasoconstriction and reduced renal perfusion[17, 279, 374]. 
 The prevention of renal failure entails the maintenance of adequate 
systemic blood pressure and the avoidance of nephrotoxic agents[347]. The 
mainstay of treatment in renal failure in ALF is early continuous renal 
replacement therapy[34, 77, 78] and cautious fluid management[347]. The 
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continuous renal replacement therapies are preferred in treating ALF 
patients, as they cause less fluctuation in hemodynamics and ICP than the 
intermittent therapy[76, 78]. 
Coagulopathy  and bleedings 
Profound coagulopathy (INR > 1.5) is always present in ALF patients due 
to their diminished production and increased consumption of coagulation 
factors, hypofibrinogenemia and thrombocytopenia[96, 292]. Coagulation 
abnormalities are usually not treated unless the patient is actively bleeding 
or an invasive procedure is contemplated[347]. Fresh frozen plasma should 
be administered with care in these patients due to the possibility of volume 
overload and a subsequent rise in ICP[270]. Furthermore, if the blood 
components are given, the trend in the plasma levels of the coagulation 
factors indicating the synthesizing capacity of the liver is temporarily lost[123]. 
Other complications, which can also occur during severe ALF, are GI 
bleeding and stress ulcers. For  this reason, every patient is given a standard 
regime of proton-pump inhibitors (e.g. omeprazole) or histamine H2-
receptor antagonists (e.g. ranitidine)[213, 270, 347].  
Infections
ALF patients are prone to both bacterial and fungal infections[282, 284, 285, 373]. 
In a study by Rolando et al., one-third of all ALF patients had a culture-
positive fungal infection[283]. Moreover, the hemodynamic changes in 
the splanchnic vascular bed are believed to cause relative hypovolemia, 
which leads to hypoperfusion and tissue hypoxia of the GI mucosa. This 
enables the translocation of gut bacteria into the blood stream, causing 
disseminating endotoxemia[23]. The diminished opsonisation of bacteria 
and the production of complement factors, as well as the breakdown of 
natural endothelial barriers, all lead to the patient having an increased 
susceptibility to infection[278].Vigilant surveillance and prompt treatment of 
the infections are essential because one of the main causes of death in ALF 
is an uncontrollable septic infection[285].
Metabolic abnormalities
Metabolic abnormalities commonly associated with ALF include 
hyponatremia, hypokalemia, hypophosphatemia and hypoglycemia 
[79, 385]. In addition, alkalosis and acidosis may both occur[96, 385]. 
Patients with paracetamol-related ALF frequently have a combination of 
hyperlactatemia coupled with acidosis, which is considered to be a poor 
prognostic sign[251]. Electrolyte and acid-base imbalance should be 
corrected promptly, as these abnormalities can increase ICP and cause 
further hemodynamic instability[239]
A Critical Evaluation Of The MARS Treatment In Finland28
Etiology-specific treatments
Only some etiologies of ALF have specific treatments available, for example, 
the N-acetylcystein (NAC) in paracetamol poisoning[48], prednisolone in 
autoimmune hepatitis[72], and penicillamine and other copper chelators in 
Wilson’s disease[306]. 
In particular, the beneficial effect of the NAC treatment has been reported 
in paracetamol intoxications[48, 134, 174] because this treatment protects the liver 
cells by acting as an antidote against the toxic metabolites of paracetamol 
(N-acetyl-p-bentzoquinoneimine, NAPQI)[49]. NAC has been shown to 
replenish hepatic glutathione stores and to improve systemic hemodynamic 
parameters by acting as a vasodilator and thereby increasing the blood 
flow and oxygen delivery to the liver[135, 276, 329]. NAC is also used in other 
etiologies of ALF[329]. According to a recent RCT[205], NAC also improved 
transplant-free survival when given intravenously in the early stages of 
non-paracetamol-related ALF.
Prognosis
Without Ltx option, the mortality in ALF can reach up to 60-95%, 
depending on the etiology[149]. During recent decades, the prognosis in 
ALF has improved significantly as a result of the possibility for a  Ltx and 
advanced ICU management. Currently, the mortality for ALF is about 20-
40% and approximately 25-45% of ALF patients undergo Ltx[202, 204, 258, 352]. A 
spontaneous liver recovery rate of 45% has been reported in a recent U.S. 
study[204].
In general, patients with hyperacute liver failure and FHF tend to 
have a better prognosis as compared to those with SFHF. Although many 
patients with FHF die, their probability for native liver recovery without 
complications is higher than for the SFHF patients[37, 253]. For paracetamol-
intoxication, acute hepatitis A and pregnancy-related ALF, the prognosis 
is relatively good with a good possibility of native liver recovery (~60%), 
whereas the prognosis is poor and native liver recovery is unlikely (~0-20%) 
in acute hepatitis B, idiosyncratic drug-induced or unknown etiology ALF, 
Wilson’s disease and autoimmune hepatitis[202-204, 258]. 
ACUTe-on-CHRonIC LIVeR FAILURe
definition 
AOCLF is usually defined as a condition in which a previously stable patient 
with chronic liver disease experiences a rapid deterioration of liver function. 
The acute exacerbation of liver function is usually caused by a triggering 
event, such as GI bleeding, infection, or ingestion of a hepatotoxic substance 
such as alcohol[319]. 
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incidence 
The incidence of AOCLF is difficult to approximate due to lack of a universally 
accepted definition for the condition. However, due to the high incidence 
of chronic liver diseases and cirrhosis worldwide, AOCLF is much more 
common condition when compared to ALF[315]. 
Patophysiology and clinical characteristics
In AOCLF, the same life-threatening organ failures occur as in ALF, including 
HE, renal failure, cardiovascular complications and severe cholestasis. 
However, some of the pathophysiological mechanisms behind these organ 
manifestations are somewhat different[319].
Characteristic cardiovascular changes in cirrhotic patients include an 
increased cardiac output, vasodilatation of the splanchnic and peripheral 
circulation, reduced renal blood flow, portal hypertension and cirrhotic 
cardiomyopathy. These changes become more pronounced during the 
acute decompensation of liver function[17]. Proposed as the mediators of 
these changes in the vascular tone have been elevated renin-angiotensin II 
secretion, sodium retention and altered nitric oxide production[17, 364].
Portal hypertension in cirrhotic patients causes shunting of the blood 
past the liver through alternative routes and this creates varices. Due to this 
portocaval shunting, gut-derived and other endogenous metabolic toxins 
escape the detoxification by the liver. Consequently, rising levels of toxins 
(e.g. neurotoxic amino acids, bilirubin, ammonia) can induce HE[53, 163, 323]. 
In spite of this, a marked rise in ICP and cerebral edema is rarely seen in 
AOCLF patients[323].
In cirrhotic patients, the hemodynamic changes described above develop 
slowly and the body has time to create compensatory mechanisms. For this 
reason, the alterations in the hemodynamic status of AOCLF patients are 
usually less pronounced than those seen in ALF patients[166]. Some studies 
have also demonstrated a decreased diastolic function and an impaired 
myocardial contractility in cirrhotic patients, which is a phenomenon called 
cirrhotic cardiomyopathy[12, 35, 272].  
etiology
Chronic liver disease can originate from numerous causes. The most 
common cause of liver cirrhosis in the Finnish population and in many other 
Western countries is the excessive use of alcohol[315]. Worldwide, chronic 
viral hepatitis is the number one cause of liver cirrhosis[315].
The most common causes of chronic liver disease leading to Ltx in Finland 
are primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic 
cirrhosis and biliary atresia (FLTR 1982-30.6.2009). Other rarer causes 
include chronic hepatitis B or C infections and non-alcoholic steatohepatitis, 
autoimmune hepatitis, and various inherited metabolic diseases (Wilson’s 
disease and alfa-1-antitrypsin deficiency). 
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special features in the conservative management of AocLF
The SMT of AOCLF aims at treating the triggering cause of the acute 
exacerbation episode and sustaining vital organ functions until compensated 
liver function is once again restored[319].  
If the patient is a candidate for Ltx and is admitted to an ICU, the SMT 
follows the same guidelines as in ALF. However, the management of AOCLF 
has a few special features distinct from ALF, which are described next.
Hepatorenal syndrome in cirrhotics
In cirrhotics, HRS can develop spontaneously but it more commonly 
occurs after a precipitating event, such as an infection, or GI bleeding[17]. 
The management of type 1 HRS usually entails a discontinuation of diuretic 
medication and a paracenthesis of ascites fluid with concomitant fluid 
replacement (20% albumin solution) and a terlipressin-infusion[17, 221, 257]. 
Some studies have reported significant improvement in renal parameters 
after the simultaneous administration of terlipressin and albumin solution[221, 
257]. One RCT including cirrhotic type 1 HRS patients showed a significant 
improvement in survival and kidney function with the MARS treatment[231]. 
Type 2 HRS is only seen in AOCLF patients. The onset of HRS type 2 
renal failure is more insidious and can take several months to develop[17].
Spontaneous bacterial peritonitis 
Spontaneous bacterial peritonitis (SBP) is defined as a bacterial infection of the 
ascites fluid in the absence of visceral perforation or other infectious focus[66, 
261]. The diagnosis of SBP demands the presence of >250 polymorphonuclear 
cells/mm3 in the ascites fluid[261]. The most common microbiological etiology 
in SBP is gram-negative GI bacteria, usually E.coli and Klebsiella species[361]. 
It has been hypothesized that in liver failure, the translocation of the gut 
bacteria into the blood stream occurs due to the dysfunctional gut-associated 
lymphoid tissue, as well as to the hypoperfusion and tissue hypoxia of the GI 
mucosa.[23, 46]. The resulting endotoxemia and colonization of the ascites fluid 
have been proposed as the principal mechanisms by which SBP develops[261]. 
Therefore, a prompt commencement of the correct antibiotic regime is 
essential, as failure to do so significantly increases mortality[361].
Prognosis
Recent studies on ICU patients have shown that the long-term prognosis 
of cirrhotic and AOCLF patients, even in the absence of complications, is 
poor and the 1-year mortality can reach up to 70%[8, 125, 214]. Prognosis in 
AOCLF depends mainly on the complications which arise and the severity 
of the underlying liver damage[214]. Short-term mortality to both GI bleeding 
and SBP in a cirrhotic patient has been reported ~20-30%[75, 261] whereas in 
type 1 HRS, mortality can reach up to ~90-100% within 6 months [17, 129]. 
According to one study, the development of progressive renal failure in 
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association with SPB in cirrhotic patients can predict a short-term mortality 
up to even 100%[116]. 
In patients with end-stage cirrhosis, the liver does not have the capacity 
to regenerate but this ability is still present in a steatotic and enlarged liver[183, 
206]. Therefore, in end-stage cirrhosis without regenerative capacity, Ltx 
remains the only long-term possibility for survival[315]. 
LIVeR TRAnsPLAnTATIon 
Despite the introduction of various liver assist devices during the past two 
decades, Ltx has still retained its place as the only validated treatment option 
in critical ALF, AOCLF and GF if conservative treatment fails[32, 149, 204, 258]. 
Even though the first Ltx was performed 46 years ago[341], it has not been 
the until the past two decades that the 1-year overall patient survival has 
exceeded 80%[353].
The first Ltx in Finland was performed in 1982 by professors Scheinin 
and Höckerstedt and their team. Since then, 777 Ltx procedures have been 
performed, including re-transplantations (FLTR, 30.6.2009). In Finland, 
the main indications for the primary Ltx have been chronic liver disease 
(71%), ALF (21%) and liver tumors (8%). In chronic liver disease, the most 
common indication for Ltx were primary biliary cirrhosis (24%), primary 
sclerosing cholangitis (20%), alcoholic cirrhosis (14%) and biliary atresia 
(8%). In transplanted ALF patients, 62% had unknown etiology and 14% 
had drug-induced liver failure. In liver tumors, hepatocellular carcinoma is 
the number one diagnosis (75%) in transplanted patients (FLTR, 30.6.2009).
For Ltx, correct patient selection is crucial. This is because a delay in 
the decision to transplant may lead to the development of complications 
and a deterioration in the clinical condition to such a point that the patient 
becomes untransplantable and Ltx is then contra-indicated. On the other 
hand, an inaccurate choice to transplant a patient who could have recovered 
without a Ltx leads to costly unnecessary major surgery and life-long 
immunosupression treatment with a possibility of serious side-effects and 
an increased risk of malignancy[93, 266, 395, 396].
Listing criteria and prognostic factors in ALF 
The traditional and validated prognostic indicators and the Ltx listing criteria 
in ALF are the King’s College criteria[251] and the Clichy criteria[36](Table 
5.). The most widely used listing criteria, the King’s College criteria, were 
introduced in 1989.  The King’s College study was based on a cohort of 588 
ALF patients who were stratified into two distinct groups: the paracetamol 
and non-paracetamol-related ALF. According to a meta-analysis, these 
criteria carry a specificity of 92% and a sensitivity of 69% in predicting 
mortality in paracetamol-induced ALF[22]. In other words, due to the low 
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sensitivity of the King’s college criteria, they may fail to recognize some 
patients who require Ltx to survive. Some transplantation centers also use 
the Clichy criteria, which were introduced already in 1986[36]. The Clichy 
criteria are based on a multivariate analysis of 115 patients with fulminant 
hepatitis B infection. 
Table 5. The King’s College and Clichy prognostic and 
transplantation listing criteria in acute liver failure
Poor prognostic signs in acute liver failure
King’s College Criteria
Paracetamol-induced 
pH < 7.3 OR all of the following INR > 6.5
 creatinine > 300µmol/l
 hepatic encephalopathy 
grade III-IV
Other causes
INR > 6.5 OR 3 of the following 40 < age < 10 
 bilirubin > 300µmol/l 
duration of jaundice before 
encephalopathy > 7 days
etiology: nonA, nonB or 
drug-induced hepatitis
INR < 3.5
  
 
 
The Clichy criteria
hepatic encephalopathy AND age < 30 and FV < 20%  OR  age > 30 and FV < 30%
In ALF, a number of other prognostic factors have been proposed with 
variable success and these include early arterial lactate [30], the APACHE 
II scoring system [179, 198], alpha fetoprotein[308, 314], the MELD-score [186], the 
ratio of the coagulation factors VIII and V[267], serum Gc (group-specific or 
vitamin D-binding) protein[201], serum phosphate levels [311] and liver size[322]. 
Listing criteria and prognostic factors in AocLF 
The severity of chronic liver disease and the need for Ltx can be assessed 
by using the Child-Pugh score[61, 211, 273] and the model for the end-stage 
liver disease (MELD)-score[118, 362, 380]. The MELD-score is used as a donor 
allocation criteria for Ltx in many countries[210]. 
The Child-Pugh-score was originally created to predict 1-year survival 
after surgery in cirrhotic patients. This score incorporates bilirubin, INR and 
albumin values and the presence of ascites and encephalopathy. Depending 
on the Child-Pugh-score, patients are assigned to three categories from A 
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to C. The predicted 1-year post-surgery survival rates are 100% in Class A, 
81% in Class B an 45% in Class C[61, 273]. 
The MELD-score, which is calculated using the INR, bilirubin and 
creatinine-values, was originally designed to predict the outcome in patients 
undergoing a transjugular intrahepatic portosystemic shunt operation[61, 273]. 
Since then, it has been validated in various patient populations and seems 
to give a reliable estimate of the short-term mortality risk of a cirrhotic 
patient[118, 170, 186, 380]. If the MELD-score exceeds 40, the patient has a less than 
20% probability of surviving the next 3 months without Ltx[118, 170, 380]. The 
Child-Pugh- and MELD-score calculators are available on the internet[362, 363]. 
contra-indications to liver transplantation
The list of absolute contra-indications to Ltx has undergone many changes 
over the past decades and differs among various Ltx centers[371]. Today, the 
only absolute contra-indications are an extrahepatic malignancy, a life-
threatening systemic disease (in which the patient is not expected to survive 
the surgery or the following ICU treatment period) or an uncontrollable 
septic infection. The relative contra-indications include portal thrombosis, 
pulmonary hypertension (mean pulmonary artery blood pressure > 
35mmHg), active alcohol or drug abuse, and psychiatric disorders causing 
an inability to comply with strict immunosuppressant protocols[210, 219, 346].
surgical techniques 
The most commonly used technique for Ltx is a full organ orthotopic 
transplant from a brain-dead donor. This method has been used since 
1963[341], but recently new techniques using living donors and split liver 
grafts have emerged as well[216]. Auxiliary liver transplants have also been 
used with encouraging results in some patients [153, 368]. Auxiliary Ltx has 
mainly been employed in FHF cases when, given enough time, the patient’s 
own liver is expected to recover. This technique provides the possibility of 
withdrawing immunosuppressant medication and sacrificing the graft once 
the patient’s own liver has regenerated.
deaths on the waiting list 
Due to the shortage of available organs and the development of complications, 
some listed patients become untransplantable or die while waiting for a 
suitable organ[118, 202, 258, 303]. In the Scandinavian countries, 4% (14/351) of all 
listed patients died on the Ltx waiting list in 2008. When considering ALF 
patients only, the percentage of patients dying on the waiting list is clearly 
higher at ~15%[42, 47, 303]. In Finland, the annual number of deaths on the Ltx 
waiting list (including both the acute and chronic patients) has varied from 
0 to 6 (0% -11%)  during 2002-2007[303].  
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Prognosis after transplantation
The survival in transplanted ALF patients is somewhat lower compared with 
the elective Ltx patients even though ALF patients tend to be younger[6, 303, 
353]. This is because the ALF patients have a higher risk of dying due to their 
higher incidence of multiple organ failure and increased ICP. Nowadays, 
in chronic hepatic disorders leading to cirrhosis, there is a tendency to 
perform a Ltx  before the development of an AOCLF episode or multiple 
organ complications[210]. 
During the past decade, the 1-year patient and graft survival rates in 
ALF after a Ltx have been reported at 61-81%  by various transplantation 
registries[303, 353] and studies[6, 107, 294]. In Finland, according to FLTR, the 1-year 
survival in ALF after Ltx is 86%. In comparison, 1-year survival rates in 
elective Ltx for chronic liver disease are over 90% in Finland and in many 
European centers[303, 353]. 
One of the most important factors determining the prognosis after Ltx 
is the etiology of liver failure[6, 51, 303, 353] as well as the recipient’s clinical 
condition, renal function and encephalopathy grade prior to the procedure 
in ALF[42, 84]. Other important predictors of outcome are the quality of the 
graft, cold and warm ischemic time[20, 42, 51] and donor/recipient’s age as well 
as the surgical technique used[6, 51, 150, 269]. 
re-transplantation
The re-transplantation rates after primary Ltx have been reported to be 
around 10%, depending on the center[7, 173, 303, 353]. In Finland, 8% (65/777) 
of all transplantations have been re-transplantations during 1982-2009. The 
most common indications for re-Ltx have been a chronic rejection (43%), 
arterial thrombosis of the primary graft (20%), other specific complications 
(8%), a primary non-functioning graft (5%), a recurrence of original disease 
(4%) and biliary complications (4%) (FLTR 30.6.2009). In fact, many studies 
have shown that the 1-year survival after re-Ltx is significantly lower (~50-
60%) when compared to primary procedures[6, 353].
LIVeR GRAFT FAILURe
After a successful Ltx, the new graft starts to function immediately. 
The stabilization of hyperdynamic circulation and disappearance of 
encephalopathy occur within the first few postoperative hours and days[210]. 
Any form of graft dysfunction has been associated with an increased 
morbidity and graft rejection[151, 346]. Early liver allograft dysfunction has 
been divided into primary non-function (PNF) and primary dysfunctioning 
graft (PDG). PNF is defined as a complete loss of graft function leading to 
patient death or re-transplantation within a week of Ltx. Its incidence has 
been reported at 2-7%[73, 346]. PDG lacks a commonly accepted definition, 
Review of the literature 35
but is generally characterized by a rise in liver enzyme levels (AST or ALT) 
over 1500 U/l within the first three postoperative days[346]. Multiple factors 
can contribute to the development of both PNF and PDG, including a 
recipient’s clinical condition prior to Ltx, donor factors (age, degree of 
steatosis of the graft, etc.), organ preservation (cold and warm ischemia 
time, etc.) and ischemia-reperfusion-injury[119, 236]. In Finland, only 0.6 % 
(5/777) of all transplanted patients have been re-transplanted due to PNF 
or PDG  (FLTR 30.6.2009) .
Late graft dysfunction, which occurs at the earliest some months after 
Ltx, usually develops as a result of the reactivation of the primary disease 
(autoimmune disease, hepatocellular cancer, hepatitis, metabolic disease, 
etc.) or chronic rejection[381].  
LIVeR-AssIsTInG DeVICes
There is a need for alternatives to Ltx due to a shortage of donor organs. 
Furthermore, some critically ill patients have a contra-indication that 
prevents Ltx. This has resulted in the innovative development and research 
of various liver assist devices during the past decades[321]. These liver assist-
devices are generally divided in two categories: (I) the bioartificial cell-based 
systems which provide both metabolic support and detoxification function, 
and (II) the artificial non-cell based detoxification systems.
i Bioartificial liver assist devices
The principle goal of the bioartificial liver assist devices (BAL) is to provide an 
extracorporeal functioning liver mass connected to the patient’s circulation. 
The history of bioartificial liver assist devices
- In the late 1960s, the first attempts at creating a biological liver assist 
treatment included cross-circulating the patient’s blood against that of a 
baboon, pig liver or a healthy human liver[1-3, 50, 275].However, it was soon 
realized that during human-to-human cross-circulation, the healthy 
person suffered from major toxic side-effects and subsequent trials were 
abandoned[50]. In animal-to-human cross-circulation, severe allergic 
and anaphylactic reactions prevented the further development of these 
techniques. Transient improvement in HE and other clinical variables, as well 
as a decrease in ammonia levels, were observed with the above-mentioned 
methods. The first hybrid BAL technique was introduced in 1986. This 
technique was based on suspension-cultured rabbit hepatocytes combined 
with a hemodialysis chamber[222]
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Functional principles
The basic functioning principle of all BAL devices is that the hepatocytes in 
the bioreactor come into direct contact with the patient’s plasma or blood 
through a membrane of selected pore size. This allows metabolic interaction 
and the passage of protein carriers but prevents the translocation of viruses, 
immunoglobulins, complements and cells[367]. In BAL systems, the patient’s 
blood is perfused across a column of hollow-fiber capillaries lined with 
hepatocytes within the extracapillary spaces either alone or attached to 
microcarriers. To remove the toxic metabolic byproducts of the BAL system 
(bilirubin, ammonia, etc.) a detoxification module is incorporated into the 
BAL device.
The exact quantity of viable hepatocytes needed to support a patient with a 
failing liver is yet unknown but based on data with hepatic resection patients, 
it has been speculated that the required hepatocyte mass is approximately 
150-450g[241, 345]. The hepatocytes in BAL devices are derived from either 
discarded human donor livers[300], immortalized human hepatoma cell 
lines[224, 225, 249, 349], porcine[59, 80, 301, 365], rat[249] or rabbit[222] origin. 
Clinical studies on the bioartificial liver assist devices
The five cell-based systems have been clinically assessed mainly in the 
phase I studies: ELAD (extracorporeal liver assist device) system[97, 229], 
HepatAssist [80], MELS (Modular extracorporeal liver support) [300, 301], BLSS 
(Bioartificial Liver Support System)[223] and AMC-BAL (Amsterdam medical 
center - Bioartificial liver) [365]. One of the most studied BAL systems, the 
HepatAssist (Cedar-Sinai Medical Center, Los Angeles, California, USA) 
using porcine hepatocytes, has been evaluated in small case series[377] and 
in a large multi-center RCT[80]. These studies have shown some success 
in improving laboratory variables and HE. Survival was also improved 
with HepatAssist therapy, even though the survival benefit did not achieve 
statistical significance except in a subgroup of patients with paracetamol-
related toxicity[80]. The first BAL systems, including the hepatoma cell line 
based ELAD, have also been investigated in RCTs[98, 229] and other studies[60, 
301, 365] with similar results. A summary of all the RCTs on BAL devices is 
presented in Table 6.
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Table 6. Randomized controlled studies on bioartificial liver assist devices 
Study Patient population System
Study 
design
End 
point
Follow-
up Outcome
Reference 
number
Ellis  et al. 
(1996)
ALF (n=24). 
Group I: not 
fulfilling 
Ltx criteria 
(n=17); 
Group II: 
fulfilled 
criteria for 
Ltx (n=7)
ELAD 
(hepatoma 
cells)
Single 
center 
RCT
Survival, 
Ltx
In hospital Survival: Group 
I: ELAD 78% 
vs. controls 75% 
(P=ns); Group 
II: ELAD 33% 
vs. controls 
25% (P=ns)
97
Millis et 
al. (2001)
ALF (n=24) 
(19 listed 
for LTx, 5 
not listed)
ELAD 
(hepatoma 
cells)
Phase 
I RCT
Survival, 
Ltx
30 days Survival: listed 
for LTx: ELAD 
83% vs. controls 
43% (P=0.12); 
transplanted 
ELAD 92% vs 
controls 43% 
(P<0.05)
229
Demetriou 
et al. (2004)
ALF (n=147), 
primary graft 
non-function 
(n=24)
The 
HepatAssist 
(porcine 
cells)
Multi-
center 
RCT
Survival, 
Ltx
30 days Survival: BAL 
71% vs. controls 
62% (P=0.26). 
Subgroups: 
ALF due to 
paracetamol: 
BAL 70% vs. 
controls 37% 
(P<0.05)
80
ALF = acute liver failure, ELAD=extracorporeal liver assist device, RCT = rand-
omized controlled trial, Ltx = liver transplantation
Limitations and future prospects of the BAL devices
There are limitations and specific concerns associated with each cell type used 
in the BAL devices. Human hepatocytes, which would be ideal to use, are 
difficult to grow in cultures and rapidly lose their liver-specific functions[293]. 
Cells from discarded human donor livers would be the second best option but 
these are in short supply and have low viability[230]. Immortalized hepatoma 
cells might present a risk of tumorgenity and the cells of animal origin are 
feared to spread xenozoonoses or to provoke immunological responses in 
patients[262]. The most used cell type at present is of porcine origin because 
it is widely available and can be easily cryopreserved[390]. Today, bioartificial 
devices are still only used in clinical studies but not in everyday clinical 
practice. One important obstacle is the extremely high price of these devices. 
The high costs, safety concerns and difficulty in obtaining or culturing 
hepatocytes, have led to the development of artificial extracorporeal liver 
assist devices.
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The future prospects of the BAL devices lie in the development of 
human stem cells which could be induced to differentiate into functional 
hepatocytes[321]. In addition, intrasplenic, intraperitoneal and intrahepatic 
hepatocyte transplantations have been investigated with some success in 
animals and humans[40, 85, 114, 133, 348]. 
ii Artificial liver assist devices
The main goal of the extracorporeal artificial liver-assist devices is to 
remove both endo- and exogenous toxins from the patient’s blood and thus 
compensate for the loss of the detoxification function of the liver through 
an extracorporeal module[334].
The history of artificial liver assist devices 
In the 1950s, before the transplantation era, the first attempts to support 
failing liver function were made by experimenting with a technology used in 
renal failure, hemodialysis[177, 228]. The next steps toward a more efficient toxin 
removal were made with blood exchange transfusion techniques[199] and 
hemoperfusion[304]. Later in the 1960s and 1970s, more advanced artificial 
blood purification methods were developed using hemoperfusion over 
charcoal[127, 250, 391] and plasma exchange (e.i.  plasmapheresis)[131, 296]. The 
plasmapheresis technique was introduced in 1968[296] and it is based on the 
filtration and removal of the patient’s own plasma and then the replacement 
of it with an equal volume of fresh donated plasma from healthy individuals. 
With these techniques, a short-lived improvement of HE and a decreased 
in the levels of ammonia and bilirubin concentrations were demonstrated, 
but no true survival benefit in the subsequent studies has been shown. In 
1988, an RCT with 137 FHF patients treated with charcoal hemoperfusion 
was published[250]. It concluded that the hemoperfusion and SMT control 
groups did not differ in survival and that the etiology of FHF was the most 
important factor in determining the fate of the patient[250].
More recently, in the early 1990s, high-volume plasmaferesis (HVPF)[64, 
182, 193, 195, 196] and single pass albumin dialysis (SPAD)[58, 65, 302] have also been 
investigated. The results from an ongoing European multi-center RCT with 
more than a hundred patients treated with HVPF has not been published yet. 
Limitations of the artificial liver assist devices
The major downfall of the plasma exchange was the non-selective removal of 
physiologically important molecules such as growth and coagulation factors. 
In plasmapheresis and single pass albumin dialysis, the substantial amounts 
of plasma or albumin needed restricted the usefulness of these methods. 
In general, the artificial liver assist devices merely act as mechanical 
filters that remove toxins from the patient’s blood. These devices are unable 
to compensate for the complex metabolic and synthetic functions of the 
healthy liver. Therefore, they can only be used as supportive therapies to 
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enable native liver recovery or as bridging treatments until a suitable organ 
is found.    
MARs TReATMenT
The new age of the artificial liver-assist devices began in the early 1990s with 
the introduction of the MARS albumin dialysis[336-339]. This was developed 
by Stange and Mitzner at the University of Rostock Germany and the first 
publications appeared in 1993[336, 337]. At present, MARS has been in clinical 
use for over ten years since 1998. 
The aim of the MARS treatment is to enable: 
1) Native liver recovery in ALF 
2) Recovery back to the compensated status in the AOCLF patients 
3) Bridging to Ltx 
4) Stabilizing the patient prior to Ltx
operational principles of the mArs machine 
The operation of the MARS machine is based on the selective removal of 
albumin-bound toxic substances and metabolites (e.g. bilirubin, bile acids, 
neuroactive amino acids) from the blood. Moreover, the MARS device is 
always coupled with a conventional hemodialysis or hemofiltration unit 
which can remove water-soluble substances (e.g. ammonia, lactate and 
urea) from the blood. 
The MARS  system  is composed of three compartments -  a blood circuit, 
a closed albumin circuit and an open single-pass dialysate circuit (Figure 3.). 
Venous access to the patient is usually achieved with a temporary dialysis 
catheter inserted into the internal jugular vein, or more rarely, into the 
subclavian or femoral vein.
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Figure 3. The MARS circuit
The patient’s blood is perfused through a hollow fiber dialysis module 
(MARSflux) across an albumin-impregnated hybrid membrane (pore size 
50kD) against a circulating albumin dialysate which is composed of 20% 
human albumin solution (Figure 4.). This membrane enables the free passage 
of small- and medium-sized molecules but prevents the translocation of 
over 50kD molecules such as hormones, clotting factors, immunoglobulins 
and cells. The endo- and exogenous toxins detach from the blood albumin 
and bind with greater affinity to the albumin impregnated in the MARSflux 
membrane and consequently pass through to the circulating albumin 
dialysate along with the concentration gradient[338]. 
Figure 4. The structure and movement of substances across the MARS membrane
[Courtesy by Prof. Marja-Leena Mäkelä, Docent Helena Isoniemi and Suomen lääkärilehti [157]]
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The fixed volume of 600ml of the albumin dialysate is composed of a 20% 
human albumin solution. The albumin dialysate is continuously detoxified by 
first circulating it through a conventional dialysis filtration column, thereby 
removing the water-soluble toxins. Next, the albumin dialysate is circulated 
through a charcoal perfusion and anion exchange resin columns and these 
remove the albumin-bound toxins (Figure 3.). In this way, a continuous 
concentration gradient is created and the purified albumin dialysate is 
once again created and ready to adsorb the toxins from the patient’s blood. 
The recommended blood flow rate is 150-250 ml/min, depending of the 
hemodynamic status of the patient and the flow rate of the albumin circuit 
is set at 150-180 ml/min[232].   
mArs treatment in clinical practice
The initiation criteria and length of a single MARS session vary greatly 
between the different centers. The only absolute contra-indication to 
the MARS treatment is active bleeding. In some centers, extracorporeal 
treatments are carried out in separate dialysis units which only operate 
during office hours but depending on the initiation criteria, the MARS 
treatment can also be given in an ICU setting. Usually, the reported length 
of a single MARS session has varied between 6-8h[95, 138, 141, 231, 320, 333]. 
The most studied etiological patient subgroup by far has been the 
AOCLF[56, 63, 89, 105, 138, 141, 145, 231, 232, 320, 375, 388]. The impact of MARS treatment 
on survival and on the surrogate end-points such as the clinical variables 
and laboratory values has been studied in many other liver failure etiologies 
with small patient groups including those induced by cardiogenic shock[95], 
following hepatic resection[156, 366], associated with sepsis and multiple organ 
failure[142, 212, 264, 281, 354], liver graft failure[122, 146, 248], and pediatric patients[18, 
69, 148, 247, 291, 354]. Refractory pruritus has also been treated successfully by 
MARS[4, 26, 27, 91, 234]. 
A recent Finnish systematic literature review on the MARS treatment 
found 22 uncontrolled studies which included more than 20 patients[157]. 
These studies encompassed a total of 160 ALF, 600 AOCLF and 100 other 
liver failure patients. However, the etiology of the patients was not stated 
clearly in all the publications. In 19 of the 22 studies, the survival rates were 
reported, but most lacked sufficient data concerning the follow-up time or 
the follow-up time was very short (e.g. 30 days or in-hospital survival)[157].
Only a few small uncontrolled case series[69, 190, 200, 317, 393] and one controlled 
prospective study[312] have been published solely on ALF patients but mostly 
these patients have been represented as a subgroup in larger studies of 
heterogeneous etiologic origins[54, 87, 246, 313, 343, 344, 376]. 
In few case reports or small case series, MARS has been used to treat 
teophylline poisoning[185] and ALF induced by leptospirosis[70], dengue 
fever[265] and Amanita phalloides mushroom poisoning[69, 207, 291, 316, 317, 389]. 
A Critical Evaluation Of The MARS Treatment In Finland42
mArs studies
Randomized, controlled trials and the meta-analysis 
Thus far only 8 RCTs[95, 138, 141, 191, 231, 320, 333, 335] have been conducted on the 
MARS treatment with a total number of 96 MARS patients. The study 
design and results of these studies are summarized in Table 7. In addition, 
a recently published abstract on the preliminary results from a French RCT 
is included in this table[298]. This is the only RCT including the ALF patients.
Only six RCT studies report survival figures[95, 138, 141, 231, 298, 320] and four 
studies showed a survival benefit favoring the MARS group to the SMT 
group[95, 141, 231, 298]. The reported 30-day survival of the MARS-treated 
AOCLF patients in RCTs has ranged from 25%[231] to 92%[141]. One study 
with 3 months follow-up showed 44% survival which was identical with 
the control group[320]. Two RCTs have been prematurely discontinued by 
ethical committees due to the increased mortality in the control group in 
the interim analysis[141, 231]. 
The majority of the RCTs conducted on the MARS patients[138, 141, 191, 231, 
320, 333, 335] have contained only the AOCLF patients with the exception of one 
study which comprised of patients with liver failure due to cardiogenic shock 
after cardiac surgery[95]. In the unpublished French multi-center study[298], 
the MARS-treated ALF patients had a higher survival as compared to the 
controls but statistical significance was not reached[298].
So far, only one  meta-analysis has been published on the MARS 
treatment[176]. This analysis concluded that MARS does not offer a significant 
survival benefit when compared to SMT. However, it also stated that at the 
moment, definite conclusions as to the efficacy of the MARS treatment 
cannot be made due to the small number of high quality studies[176]. 
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Outcome and survival in the uncontrolled studies 
Survival of the MARS-treated patients has been reported by a vast number 
of uncontrolled studies[162, 246, 344, 388, 393]. However, comparison between these 
results is challenging due to the  considerable variation in the follow-up 
time from 30 days to 3 years as well as the unequal availability of transplant 
organs in the different countries. Furthermore, indications for the MARS 
treatment and thus the severity of liver failure differ substantially between the 
centers and studies. In addition, many reports lack sufficient data concerning 
follow-up time, and outcome has been reported for a heterogeneous group 
of patients without distinguishing between different etiologies (AOCLF, 
ALF and GF). Moreover, some centers classify alcoholic hepatitis, acute 
exacerbation episodes of chronic viral hepatitis and posthepatectomy 
dysfunction as ALF[54, 246, 376].
Outcome and survival in the MARS-treated ALF patients: Overall survival 
(including both transplanted and non-transplanted patients) has been 
reported around 60-70%[54, 62, 87, 190, 200, 244, 246, 344, 393]. Due to the low prevalence 
of ALF, most published reports are small case series with very few patients. 
The outcome of the MARS-treated ALF patients in different studies are 
presented in Table 8. excluding studies containing children[247], case series of 
pure Amanita-intoxications[69, 316, 317], or missing outcome data[109, 274, 313, 343, 387].
For comparison, a large national U.S. study including 17 centers reported 
the overall survival of the ALF patients at 67% at 3 weeks. In this U.S. study, 
43% of the patients survived without Ltx. The short-term transplant-free 
survival varied greatly, from 68% for the patients with paracetamol-related 
liver failure to 25% and 17% for those with other drug reactions and an 
indeterminate cause, respectively[258]. Another study reported that 45% of the 
adult ALF patients experienced spontaneous liver recovery, 25% underwent 
Ltx and 30% died without Ltx[204].  
The mortality from Amanita poisoning related ALF is estimated to 
be around 6-18% with many patients requiring Ltx[99, 121, 159]. A few case 
reports[152, 207, 291, 389]and small case series[69, 316, 317] have been published on the 
MARS treatment in severe Amanita poisoning with survival results ranging 
from 67% (4/6)[69] to 71% (10/14)[317]. 
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Table 8. The outcome of the acute liver failure patients in observational studies
Study Patient population
Study 
design
Follow-
up time
Length 
of MARS 
session
Ltx & Survival Other results Reference number
Novelli 
at al. 
(2002)
Total 34; 
ALF 9
Case 
series
Not 
reported
8h 67% of the ALF 
patients transplanted. 
Survival: 67% in 
transplanted and 
100% in non-
transplanted patients
Significant decrease 
in  bilirubin and 
ammonia.
244
Steiner 
at al. 
(2002)
Total 176; 
ALF 38
Case 
series
Variable Variable Overall survival: 
50%, transplant-
free survival: 34%
Significant 
improvement 
in HE and the 
MELD-score 
and a decrease in  
bilirubin, creatinine, 
urea, albumin 
and ammonia.
344
Zhou 
at al. 
(2004)
drug 
induced 
ALF 14
Case 
series
6 
months
8h Overall survival and 
native liver recovery 
rate 79%. None 
were transplanted. 
Significant 
improvement in 
most laboratory 
variables.
393
Di 
Campli 
et al. 
(2005)
Total 20; 
ALF 3
Case 
series
3 
months
Not 
reported
2 transplanted 
patients survived and 
1 non-transplanted 
patient died.
Significant 
improvement in HE. 
Significant decrease 
in  bilirubin, bile 
acids, creatinine 
and ammonia.
87
Lai 
et al. 
(2005)
ALF 10 Case 
series
Not 
reported
8h Overall survival: 30%, 
2 patients received 
Ltx and died. 
Significant increase 
in systemic vascular 
index and reduction 
in cardiac index, 
urea and creatinine.
190
Lee 
et al.   
(2005)
drug 
induced 
ALF 13
Case 
series
6h 2 patients survived 
of which the other 
received Ltx. The 
other 11 patients 
died without Ltx.
Significant decrease 
in bilirubin.  
200
Novelli 
et al. 
(2005)
Total 116; 
ALF 24
Case 
series
Not 
reported
9h 75% of the ALF 
patients transplanted. 
Survival 58% in 
the ALF patients
Significant decrease 
in bilirubin, 
ammonia, 
creatinine.
246
Camus 
at al. 
(2006)
Total 22; 
ALF 14
Case 
series
30 days 8h Survival in the ALF 
patients only not 
reported. The overall 
spontaneous liver 
recovery rate 32% and 
survival 68%. Survival 
89% in listed and 54% 
in non-listed patients.
Significant decrease 
in bilirubin 
and increase in 
prothrombin-index.
54
Chiu 
et al. 
(2006)
Total 22; 
ALF 2
Case 
series
30 days 6h 1 patient transplanted 
and survived, 1 
patient survived 
without Ltx.
Significant decrease 
in bilirubin, 
ammonia, and urea.
62
ALF=acute liver failure, MELD= end-stage liver disease score, HE= hepatic encephalopathy
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Outcome and survival in the MARS-treated AOCLF patients: In case 
series, the short-term (30 day - 3 month) survival of mostly nontransplanted 
MARS-treated AOCLF patients has been reported between 30-65%[87, 331, 339, 
340, 344]. The out-of-hospital survival rates for the nontransplanted alcohol-
related AOCLF patients vary between 21%-63% [162, 388] and a 1-year survival 
was reported at 58% by Hessel et al.[145].
Outcome and survival in the MARS-treated graft failure patients: A recent 
study on the MARS-treated early GF patients reported a 28% transplant-free 
survival rate and a 60% survival in the re-transplanted patients[248]. In the 
other small uncontrolled studies, the short-term survival in early and late 
GF patients who received MARS treatment has been reported between 25% 
to 67%[62, 122, 146, 344]. The survival in the MARS-treated post-hepatectomy liver 
failure patients has varied significantly between centers (0-71%)[62, 156, 366].
Effect on encephalopathy, cerebral perfusion and plasma amino acids
Significant improvement in neurological function, HE and the Glascow 
Coma Scale has been reported in a vast number of the MARS studies[54, 63, 
232, 260, 339, 344] including three RCTs[138, 141, 320]. In the RCTs, the grade of the HE 
decreased significantly whereas in the controls, it increased[138, 141, 320]. Some 
studies have even described a complete resolution of the HE grade 4 coma 
with the MARS treatment[132, 189]. In addition, normalization of the cerebral 
perfusion pressure[28, 245, 310] has been noted during the MARS treatment.
A few reports have described a decrease in the plasma AAAs and in the 
tryptophan concentration, and a subsequent improvement in the Fischer’s ratio 
in the encephalopathic AOCLF and the ALF patients treated with MARS[209, 260, 
313]. It has been speculated that the improvement in the amino acid dysbalance 
might correlate with the simultaneous improvement in HE[209, 260, 313].
Effect on the hemodynamic variables  
The stabilization and improvement in the hemodynamic parameters and the 
attenuation of hyperdynamic circulation have been reported during MARS[56, 
89, 132, 190, 191, 248, 274, 309]. In an RCT by Laleman et al., a significant improvement 
of the MAP and systemic vascular resistance index were noted with MARS 
treatment while the cardiac index remained unchanged. Furthermore, a 
simultaneous decrease was recorded in plasma renin activity, aldosterone, 
norepinehrine, vasopressin and nitrate[191]. Another prospective controlled 
study on MARS-treated ALF patients reported a significant decrease in 
cardiac index and heart rate, whereas the systemic vascular resistance index 
and MAP increased when compared to the controls[312]. Uncontrolled case 
series have also reported a decrease in portal hypertension and renal/splenic 
resistance indexes after the MARS treatment in the AOCLF patients[56, 89]. 
Another benefit of the MARS treatment is a reduced need of vasoactive 
medication[248]. These changes have been speculated to arise from the removal 
of the albumin-bound vasoactive substances such as nitric oxide[89, 132]. 
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Effect on the albumin-bound and water-soluble substances/toxins 
In the first in vivo and in vitro studies, it was noted that the MARS treatment 
was able to remove the low- and middle- molecular weight albumin-bound 
substances (such as copper, bilirubin, bile acids, aromatic amino acids, 
tryptophan, endogenous benzodiazepine-like substances and nitric oxide) 
as well as the water-soluble toxins (ammonia, creatinine, lactate and urea) 
from the patient’s blood[336, 337, 339]. These findings have been reproduced by 
RCTs[95, 138, 141, 191, 231, 320, 333, 335] and other MARS studies[62, 102, 344, 360, 388]. 
A clinically and statistically significant reduction in the plasma levels 
of bilirubin, creatinine, urea and ammonia have been noted in most of the 
previously quoted MARS studies. On the other hand, the in vitro studies 
using the plasma from ALF patients have been shown to induce apoptotic 
pathways in human hepatocyte cultures as compared to the plasma from 
healthy patient[225]. This apoptosis-inducing ability did not decrease after the 
MARS treatment, suggesting that there are some residual toxic mediators 
in the plasma of the ALF patients which cannot be removed by MARS[297]. 
Effect on the plasma cytokines 
Elevated plasma cytokine levels have been proposed as one of the mediators 
of hepatocyte necrosis and the development of HE[139]. The cytokine profiles 
of MARS-treated ALF and AOCLF have been investigated in a number of 
studies[14, 18, 88, 154, 155, 158, 320, 333] with conflicting results. Most studies, including 
our own center’s research[154, 155, 158], have concluded that the MARS treatment 
is able to remove cytokines from the blood but it does not change the cytokine 
profile of the patient in a clinically significant manner.
The cost-utility and impact on the health-related quality of life  
The cost-utility of the MARS treatment and its impact on hospitalization 
costs has been investigated  in a few small nonrandomized studies containing 
only AOCLF patients[137, 143-145]. Moreover, three of these studies have been 
conducted in the same center in Essen Germany[143-145]. The health-related 
quality of life (HRQoL) or cost-effectiveness of MARS treatment in ALF 
patients has not been studied previously.
The study by Hassanein et al. contained only 12 patients and it compared 
the direct in-hospital medical costs associated with the MARS treatment 
to a control group receiving SMT in the alcohol-related cirrhotic AOCLF 
patients in the U.S.. The hospitalization costs in the MARS-treated surviving 
patients were $32,036 which was $4,000$ less than in the control group[137]. 
A recent cost-utility study on alcohol-related AOCLF patients in Germany 
concluded that the mean direct medical costs during 3 years were 40,032€ with a 
survival rate of 52% in the MARS treatment group. The incremental costs per life-
year gained was 31,400€ and the incremental costs per quality adjusted life year 
(QALY) gained was 47,200€[145]. However, the aforementioned study excluded 
all patients who underwent Ltx or had a serious concomitant co-morbidity.
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Side-effects and safety considerations 
The most common side-effects reported in association with the MARS 
treatment include decrease in  platelet count and/or moderate bleeding 
complications (mucous bleeding or bleeding from the insertion site of the 
dialysis catheter) and catheter infections[4, 54, 104, 109, 191, 231, 237, 274]. One case of 
non-cardiogenic pulmonary edema has been reported[90] but other serious 
life-threatening complications have not been documented. In review articles 
MARS has been considered a safe treatment[318, 351].
comparison between the mArs and the 
Prometheus albumin dialysis systems  
The introduction of the MARS device was followed shortly thereafter by 
the presentation of another albumin dialysis system in 1999; the Fractioned 
plasma separation, adsorption and dialysis (i.e. Prometheus)[106, 277]. Although 
both the MARS and the Prometheus systems are basically albumin dialysis 
machines, there are two fundamental differences between them. Firstly, in 
the MARS machine, the albumin dialysate is circulated in a separate closed-
loop system, whereas in Prometheus, the patient’s plasma and albumin are 
separated from the blood for filtration. Secondly, the Prometheus device 
has a much bigger filtration pore size as compared to the MARS (250kD 
vs. 50kD) which allows the passage of larger molecules such as albumin 
(68kD) into the secondary circuit[106, 336, 337]. Due to the larger pore size in the 
Prometheus system, the filtration and adsorption of some coagulation factors 
can lead to major coagulation disturbances and consequently to repeated 
thrombosis[227]. A significant prolongation of the prothrombin time[104] and 
the reduction of several coagulation factors (II, X and protein S and C) have 
been reported with the use of the Prometheus system[227], while the levels 
of factor V and VIII have remained unchanged due to the bigger molecular 
weight (>300kD) of these molecules[227, 277].
Some comparative studies have been carried out between the MARS and 
the Prometheus systems[104, 187], including three RCTs[191, 333, 335]. Both devices 
have been shown to decrease water- soluble and albumin-bound toxin 
levels in the blood much in the same manner[103, 191, 333, 335]. A recent study 
of 18 patients found that the Prometheus demonstrated a higher removal 
rate of most toxins (bilirubin, urea, creatinine) as compared to the MARS 
treatment[104]. On the other hand, Laleman et al. found that the MARS 
treatment was able to improve the hemodynamic profile in the cirrhotic 
AOCLF patients, whereas Prometheus did not[191].
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AIMS OF THE STUDy
The main goal of the present studies (I-VI) was to evaluate the outcome of 
195 MARS-treated patients in Finland and to answer the most important 
and clinically relevant question associated with this treatment. 
The specific aims of this thesis were:
1) To study the effect of the MARS treatment on patient outcome (survival, 
native liver recovery and need for Ltx) in different liver failure etiologies 
(II, III, IV, V, VI).  And also, to determine which patients stand to gain 
and who do not benefit from MARS treatment. 
2) To explore prognostic factors predicting survival in MARS-treated 
patients in various liver failure etiologies (V). 
3) To investigate the impact of MARS treatment on the plasma amino acid 
profile (I) and encephalopathy (I, II, IV, V) in  liver failure patients.
4) To investigate the impact of MARS treatment on laboratory values and 
albumin bound toxin levels (I, V).
5) To examine the direct medical costs and the cost-utility of MARS 
treatment and its impact on the HRQoL of the patient in an ICU setting 
(VI). 
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PATIENTS AND SETTING 
This thesis includes 188 MARS-treated liver failure patients in Finland 
during May 2001-March 2007. Four of these patients were treated both 
before Ltx due to their liver failure and afterwards, due to their graft failure 
and they are considered to be individual treatment cases as categorized by 
etiology. Study III and IV featured seven additional ALF patients treated 
during April 2007 - September 2007. The total number of MARS-treated 
patients in this thesis was 195. 
A historical control group of 46 consecutive ALF patients treated during 
January 1995 - April 2001 was included in Study II. This patient population 
and time period was selected to include a satisfactory number of patients 
for a comparative analysis within such a time interval that the SMT of the 
liver failure patients would be similar to the MARS era. In Study VI, a more 
contemporary control group was used of 17 ALF patients treated during 
March 2000 – April 2001. This was done in order to compare the treatment 
costs within a relatively small time window to minimize the impact on the 
final results of inflation, price changes and the currency conversion. In 
addition, from the year 2000 onwards, the HUCH district began to use the 
clinical patient-administration database Ecomed® (Datawell Ltd., Espoo, 
Finland) for registering treatment costs. 
During the past decade, a handful of patients has also received The MARS 
treatment at the University hospitals of Tampere and Oulu in collaboration 
with the Surgical Hospital[157], but generally, the MARS machine in Tampere 
has been used in research projects. Moreover, in a few cases, nurses from 
the Surgical Hospital who are specialized in giving the MARS treatments, 
have performed the MARS treatments in the Children’s Hospital and the 
Cardiac ICU of HUCH. However, only the patients treated at the liver ICU 
of HUCH were included in this thesis.   
defining liver failure categories
The term ALF is defined in this dissertation as a deteriorating liver function 
(increasing liver enzyme and bilirubin levels and/or decreasing coagulation 
factor levels) with or without encephalopathy in a person with no previous 
history of liver disease. Furthermore, ALF is used as an umbrella term 
encompassing the hyperacute, acute and subfulminant subtypes. The patients 
in Studies I-VI are subgrouped according to the specific etiology of their 
liver failure. 
AOCLF was defined as an acute decompensation episode of liver function 
in a previously well-compensated chronic liver disease patient. AOCLF 
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often developed rapidly due to a triggering cause (such as an infection or 
GI bleeding). 
The GF patients included both those that had early and late graft 
dysfunctions. The group of miscellaneous etiologies contained one case 
of acute hemorrhagic pancreatitis, one case of ischemic injury to the liver 
following myocardial infarction, one multiple trauma patient with chronic 
hepatitis C and three post-liver resection hepatic failures.
mArs treatment indications and the 
treatment protocols in Finland 
The initiation criteria for the MARS treatment in Finland depend on the 
etiology of the liver failure (Table 9.). The recommended flow rates of blood, 
albumin and dialysate circuits in our unit are presented in Table 10. In some 
patients, the MARS treatment was started without signs of HE, particularly 
in ALF patients who had ingested a lethal amount of toxin (e.g. paracetamol, 
Amanita), or if laboratory parameters indicated progressive liver failure 
(increasing liver enzyme and bilirubin levels and/or decreasing coagulation 
factor levels) despite the best possible SMT. 
The diagnosis of Amanita phalloides  poisoning (III) and the decision 
to start the MARS treatment was based on 1) the information given by the 
patient (all had eaten white mushrooms resembling Amanita phalloides) and 
2) the appearance of typical symptoms within 24h of mushroom ingestion 
(i.e. vomiting, abdominal pain and diarrhea) .
In critical ALF, treatment was usually discontinued only to replace a new 
dialysis absorption kit to the machine. As a general rule, we only treated the 
first exacerbation episode of chronic alcoholic liver disease.
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Table 9.  MARS treatment initiation criteria and treatment protocols in Finland.
Etiology MARS treatment initiation criteria Treatment protocol
Acute  
liver failure
Rapid deterioration of the clinical 
condition and hepatic synthetic function 
despite standard medical therapy 
22 hour sessions daily until:
AND one of the following criteria: 1) Native liver recovers
1) Ingestion of a lethal dose of known hepatotoxin 
(mushroom, paracetamol, iron, etc.)
2) Suitable transplant 
organ is found
2) Patient fulfills the criteria for high urgent Ltx 3) Irreversible multi-
organ damage occurs
Acute-on-
chronic  
liver failure
Rapid deterioration of the clinical 
condition and hepatic synthetic function 
despite standard medical therapy 
6-8 hour sessions based on the 
daily assessment by the surgeon 
and anesthesiologist until:
AND two of the following criteria: 1) Patient’s clinical 
condition improves
1) Hyperbilirubinemia, bilirubin >400µmol/l 2) Suitable transplant 
organ is found
2) Type 1 Hepatorenal syndrome  3) Irreversible multi-
organ damage occurs
3) Progressive hepatic encephalopathy 
Graft failure
No set criteria, depends on the assessment of 
the transplant surgeon and anesthesiologist 
No set protocol, based on 
the daily assessment by the 
surgeon and anesthesiologist 
Table 10. The flow rates of the MARS circuit
↔ = plasma level within normal range, ↑= plasma level elevated
electrolyte balance and anticoagulation 
during the mArs treatment 
The blood gas analysis and the plasma levels of  potassium, magnesium, 
and phosphate are controlled every 6 hours to ensure optimal electrolyte 
balance. Hypokalemia and hypomagnesemia are promptly corrected with a 
potassium chloride-infusion and magnesium sulphate-boluses, respectively. 
Bilirubin Creatinine Ammonia
Blood flow 
(ml/min)
MARS circuit 
(ml/min)
Dialysate flow 
(ml/min)
Ultrafiltration 
(min. ml/min)
↔ ↔ ↔ 150-180 150 500 400
↑ ↔ ↔ 180 180 500 400
↔ ↑ ↑ 150-180 150 500-800 1000-1200
↑ ↑ ↑ 180 180 500-800 1000-1200
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The blood phosphate-ion–balance is controlled by a continuous infusion 
of a solution containing phosphorus. The saturation of the MARS filters is 
monitored by taking bilirubin samples taken every 6 hours. 
Anticoagulation is used if permitted by the coagulation status and platelet 
count to prevent the clotting of the MARS filters.  If the patient’s INR is 
below 3, dalteparin  can be used. An epoprostenol-infusion (ad 5 ng/kg/
min) is used either alone or in combination with dalteparin if the platelet 
count is over 50x109/l. If coagulation problems persist despite the dalteparin/
epoprostenol medication, and antithrombin III levels decrease below 15%, an 
antithrombin III preparation is given. If the patient shows signs of bleeding, 
the dosage of anticoagulants is reduced or the medication is discontinued. 
If the INR is above 3 and the platelet count below 50x109/l, anticoagulation 
is not given.
standard medical therapy of the liver failure patients
All patients received a similar SMT at the same liver disease specialized 
4-bed ICU and Ltx unit at the Surgical Hospital of HUCH. The SMT follows 
the same guidelines as presented in the chapters describing the current 
conservative management of ALF and AOCLF. The only major exception 
to the general SMT was the use of HVPF and invasive ICP monitoring in 
some control group patients before the MARS era (II).
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METHODS 
Prospectively collected data:
Since the introduction of the MARS treatment in Finland in May 2001, 
the information  regarding each patient and treatment session has been 
prospectively collected to a specifically designed data collection sheet. 
The patients were stratified before treatment into etiological subgroups: 
ALF, AOCLF, graft failure, postresection or other indications. The cause 
of liver failure was recorded in more detail. Pre-existing liver disease-
related complications (HRS, encephalopathy, ascites, GI bleeding, SBP, 
hyperbilirubinemia) were also recorded. 
In all patients, the baseline demographics, laboratory (cell counts, 
coagulation factor levels, liver transaminases, bilirubin, ammonia, urea, 
creatinine, blood gases, and electrolytes) and clinical variables (grade of HE, 
renal failure, ascites, MAP, need for mechanical ventilation and vasoactive-
infusions) were recorded at the beginning of the first and after the last MARS 
session. MARS treatment-related data were also collected for the same case 
record forms (e.g. timing, number and duration of sessions, flow rates of the 
albumin, blood and dialysate circuits and treatment related complications). 
At baseline, the MELD-score was calculated for each patient using the 
standard formula by the United Network for Organ Sharing[362].
The same data variables were collected retrospectively from each control 
group patient (II, VI). In addition, the use of other extracorporeal treatments 
(e.g. HVPF) was recorded. The baseline data was collected upon the patient’s 
admittance to the ICU. The post-treatment values were obtained  before 
leaving the ICU, Ltx or before death. 
In Studies II-VI, the rates of survival, native liver recovery and Ltx were 
determined after the follow-up period. Table 11. offers a summary of the 
study type, number of patients, and the main outcome variables of studies 
I-VI.
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The specific methodology used in Studies I-VI:
Study I: The plasma concentration of the neuroactive amino acids were 
measured using a liquid chromatography (and the Fischer’s ratio determined) 
before and after the MARS treatment. Statistical methods were then used to 
analyze the differences in the amino acid levels before and after the MARS 
treatment and also their correlation to the grade of HE were determined 
in different etiologies. The levels of amino acids before and after treatment 
were compared between the ALF and AOCLF patients.
Study II: For the comparison of outcomes (survival, native liver recovery 
and need for Ltx) between the MARS and the historical control ALF group, 
patients were subdivided into etiological subgroups. This was a way to match 
up the patients who had similar prognoses. All patients received the same 
SMT with the exception of the HVPF which was used in 12 control group 
patients.
Study III: Every patient received the standard SMT for mushroom poisoning 
(including fluid resuscitation, NAC, and activated charcoal). The time 
which had elapsed was determined from the mushroom ingestion to 1) the 
appearance of symptoms 2) the first aid at local hospital and 3) the beginning 
of MARS treatment.
Study IV: The time from the listing and the MARS treatment to the Ltx were 
determined. The pathologist then determined the weight, histopathology 
and degree of necrosis in the explanted liver. Patients were analyzed and 
subgrouped according to degree of necrosis in their explanted liver: group 
I: 100% (n=10), group II: >80% (n=9) and group III: <80% (n=18) necrosis. 
Study V: All patients were categorized according to their liver failure 
etiology. A stepwise logistic regression analysis was used to search for 
prognostic factors predicting 6-month survival in each etiological subgroup. 
The variables analyzed included all the collected demographic, clinical and 
treatment-related variables and all the laboratory parameters at baseline.
Study VI:. All the direct liver disease-related costs were obtained from the 
Ecomed-database for the period of 6 months prior to treatment until 3 years 
afterwards. Only those patients living in the Helsinki Uusimaa hospital 
district were included in the cost analysis. The costs in the Ecomed-database 
include the ICU and ward costs, ambulatory visits, laboratory and radiology 
costs, surgery and procedure costs, expensive medicine and blood products. 
The HRQoL of MARS patients was measured with a generic self-
administered questionnaire, the 15D instrument, using the questions 
related to 15 dimensions: moving, seeing, hearing, breathing, sleeping, 
eating, speech, eliminating, usual activities, mental function, discomfort 
and symptoms, depression, distress, vitality, and sexual activity. For each 
dimension, the patient or doctor selected one of five levels that best described 
the patient’s current state of health. A set of utility weights was used to 
generate the 15D score, ranging from 0 to 1 (1=healthy state, 0=dead)[325]. 
For most of the important properties, i.e. the reliability, content validity, 
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discriminatory power, and responsiveness to change, the 15D compares 
favorably to other similar HRQoL instruments such as the EQ-5D, SF-6D, 
HUI3, and AqoL [140, 235, 326-328, 342]. 
Upon ICU admittance, the HRQoL of the patient was estimated by three 
ICU doctors, retrospectively, by using the 15D instrument and the patients’ 
clinical documents. The post-treatment HRQoL was measured by sending 
the 15D questionnaire to all the surviving MARS-treated patients. A 15D 
score three years after the first MARS treatment was estimated for each 
patient using a linear regression analysis. 
In the cost-utility analysis, the effectiveness of the MARS and SMT was 
measured as the quality-adjusted life years (QALYs) gained. The QALYs 
gained were estimated by determining the difference in the HRQoL before 
and after treatment and the resulting survival benefit within 3,5 years time. 
Also, the total direct medical costs and outcomes of MARS treatment were 
compared with those in the control group over a 3.5-year time horizon 
from the perspective of the health care provider. The incremental cost-
effectiveness ratio (ICER) was determined by dividing the difference in costs 
by the difference in QALYs. 
Statistical methods
Data in Studies I and IV was analyzed with StatView5 for Windows (SAS 
Institute Inc.). All other data in Studies II, III, V and VI were analyzed by 
the SPSS for Windows version 15.0. and 16.0 (SPSS, Chicago, IL).  The P ≤ 
0.05 was considered to be statistically significant. The results were presented 
as a mean (+ standard deviation) or a median (minimum-maximum). 
The missing laboratory values were replaced by the median value of that 
laboratory result in all patients. The median value and the use of non-
parametric tests were selected due to the skewed distribution of most results.
The following statistical methods were used in this thesis. 
Wilcoxon signed rank-test Repeated scale measurements (laboratory 
results, etc.) before and after treatment 
within a single treatment group.
Mann-Whitney-U  –test Comparison of the scale measurements between two 
independent treatment groups (MARS vs control).
Kruskall-Wallis test Comparison of the scale measurements between 
three on more independent groups.
Pearsons χ2 and Fisher’s exact tests Comparison of the outcomes and bionominal 
results between independent groups.
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Additional statistical methods 
Study I: Variance analysis 
Study II: To compare the survival of the MARS and the control group, the 
Kaplan-Meier method and the log-rank test for cumulative survival over 
time was used.
Study V: To explore the factors predicting the survival in each etiological 
subgroup, a stepwise binary logistic regression analysis was used. The odds 
ratio (OR) and confidence interval (C.I.) for each predictive variable was 
calculated. The best combination of the significant predictive variables was 
selected using the R2-score and Hosmer-Lemeshow Goodness of Fit-test. 
Study IV: To estimate the effect of the model parameter uncertainty on the 
results, a one-way and probabilistic sensitivity analysis were used. In the 
one-way sensitivity analysis, the discount rate of costs, the mean costs and 
QALYs of both MARS and control treatment, the probability of Ltx, and 
survival rates, were varied. A regression analysis was used to estimate the 
overall costs and HRQoL 3 years after treatment for all patients. 
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RESULTS
The distribution of the liver failure etiologies in the MARS group (V) and 
the ALF control group (II) are shown in Figure 5. The other ALF subgroup 
contained a heterogeneous combination of rare ALF etiologies (e.g. 
pregnancy related ALF, acute viral hepatitis, ischemia, etc.). The fourth main 
group, other etiologies, included miscellaneous liver failure patients who 
were difficult to categorize under the ALF, AOCLF or GF (e.g. pancreatitis, 
post-resection hepatic failure, trauma, etc.). 
Figure 5. Distribution of liver failure etiologies
MARS GROUP
n=192*
ALF
n=113
Toxic 
n=63
Paracetamol-related n=32
Non-paracetamol-related n=31
Unknown 
n=41
Other
n=9
AOCLF
n=62
Alcohol-related
n=45
Cirrhotic liver n=34
Steatotic/enlarged liver n=11
Other
n=17
GF 
n=11
Early GF n=8
Late GF n=3
CONTROL GROUP
n=46
ALF
n=46
Toxic 
n=12
Paracetamol-related n=6
Non-paracetamol-related n=6
Unknown
n=26
Other
n=8
Other
n=6
ALF=acute liver failure, AOCLF=acute-on-chronic liver failure, GF= graft 
failure * = 4 patients were included in both the liver failure and GF groups.
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Baseline characteristics of the mArs-treated patients
The baseline characteristics of the 192 MARS-treatment cases in Study V 
are summarized in Table 12. All AOCLF patients belonged to the Child-
Pugh class C. 
Table 12. Demographic, clinical, and treatment data at the 
beginning of the MARS treatment in Study V.
All demographic values are expressed as median (range) or as a percentage % 
of patients (number of patients).  ALF = acute liver failure, AOCLF = acute-on-
chronic liver failure, MELD = Model for end-stage liver disease-score, Ltx = liver 
transplantation
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The comparison of the baseline characteristics between the MARS and the 
control ALF patients (II) are presented in Table 13.
Table 13. Comparison of baseline data between the MARS 
and the control group ALF patients in study II. 
ALF PATIENTS
Baseline demographic & clinical data MARS Control P
Number of patients 113 46
Age in years 45 (14-81) 45 (21-72) 0.952
Sex %, male 41% (46) 35% (16) 0.591
Contraindication to Ltx 
prior to treatment %
14% (16) 13% (6) 0.853
Mechanically ventilated % 33% (37) 33% (15) 1.000
Vasoactive-infusion used % 31% (35) 33% (15) 0.853
Renal insuffiency % 35% (40) 44% (20) 0.370
MELD-score 31 (5-50) 34 (19-51) 0.020
Encephalopathy grade before treatment 1.8 (1.5) 2.0 (1.4) 0.433
Platelets x109 135 (11-511) 137 (18-448) 0.459
Creatinine µmol/l 83 (35-1318) 84 (35-673) 0.505
NH4-ion µmol/l 75 (8-512) 94 (14-407) 0.169
Bilirubin µmol/l 290 (4-761) 368 (38-880) 0.083
ALT  U/l 943 (11-12500) 905 (47-12280) 0.899
TT % 20 (6-80) 16 (6-51) 0.069
All values are expressed as a median (range) or as a percentage % of patients (number 
of patients).  The encephalopathy grades are expressed as a mean (±standard devia-
tion). MELD = Model for end-stage liver disease-score, Ltx = liver transplantation, 
NH4-ion = ammonium-ion, ALT = Alanine aminotransferase, TT % = thrombin time 
(includes coagulation factors II, VII, X).
Patient outcome
Figure 6 shows the 1-year outcome of the 188 MARS treated patients in 
Study V in terms of their native liver recovery, survival and need for Ltx.
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Figure 6. The 1-year outcome of 188 MARS treated patients in study V.
ALF = acute liver failure, AOCLF = acute-on-chronic liver failure
Overall survival
The 1-year survival of all 188 MARS-treated patients was 57%. The highest 
overall survival was observed in the toxic etiology ALF subgroup (79%) and 
the lowest survival in the alcohol-related AOCLF (22%), and for the other 
miscellaneous etiology liver failure subgroups (17%). The 1-year survival of 
the transplanted  and non-transplanted patients in Study V were 86% and 
47%, respectively (Figure 7.).  
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Figure 7.  The 1-year survival of the transplanted and 
non-transplanted MARS-treated patients
The total sumber of patients in each subgroup is presented above the cor-
responding column. 
ALF = acute liver failure, AOCLF = acute-on-chronic liver failure
ALF 
In Study II, the 6-month survival of both the transplanted (94% vs. 77%, P= 
0.06) and non-transplanted (66% vs. 40%, P=0.03) ALF patients was higher 
in the MARS treatment group as compared to the controls. Furthermore, the 
percentage of patients who died during treatment due to tentorial herniation 
was significantly lower in the MARS group (4% vs. 15%, P=0.014). However, 
it was noted that the etiological distribution of the ALF patients who have 
been referred to our transplantation ICU, has changed markedly over the 
past ten years (P=0.002) toward the more benign toxic etiologies (Figure 5.). 
The baseline comparison of the demographic, clinical and laboratory data 
before treatment shows that despite significant differences in the etiological 
distribution and the MELD-scores, the groups are otherwise similar (Table 
13.)
In the subgroup analysis of Study II, the patients with unknown etiology 
ALF in the MARS and the control groups were comparable at all measured 
baseline variables. There was a trend towards higher 6-month survival in 
the MARS group (71% vs. 50%, P=0.09) even though statistical significance 
was not achieved. In the toxic etiology subgroups, the MARS and the control 
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groups differed significantly at the baseline HE grades and MELD-scores. 
Moreover, all patients with Amanita mushroom poisoning survived the 
1-year follow-up (III). 
In Study IV, the 1-year survival of ALF patients who underwent high 
urgent Ltx was 92%. In Study VI, the percentage of ALF patients who 
survived over 3 years after treatment was significantly higher in the MARS 
treatment group as compared to the controls (78% vs. 41%, P= 0.002)  in 
Study VI.
AOCLF 
The 1-year survival of the transplanted and non-transplanted patients were 
100% and 19% in the alcohol-related AOCLF, and 67% and 13% in the other 
etiology AOCLF (V). In the alcohol-related AOCLF, the patients exhibiting 
signs of steatosis and enlargement of the liver had significantly higher 1-year 
survival when compared to those with end-stage cirrhosis (55%  vs.  6%, 
P=0.002).  
GF
The overall 1-year survival rate was 73% in 11 patients. The 1-year survival 
of the re-transplanted and non-re-transplanted patients were 83% and 60%, 
respectively. Sixty-two percent of the early GF patients survived and four 
were re-transplanted. All 3 patients with late GF survived and two were re-
transplanted successfully.
Native liver recovery and Ltx
In Study V, 26% of the 188 patients were transplanted. Native liver recovery, 
which was defined as a survival of over 3 months without Ltx, occurred in 
35% of  the patients (Figure 6). 
ALF 
In Study II, the percentage of patients who experienced native liver recovery 
was significantly higher in the MARS group as compared to the controls 
(49% vs. 17%, P<0.001). Furthermore, the percentage of Ltx was lower in the 
MARS treatment group (29% vs. 57%, P=0.001). In the subgroup analysis 
of the toxic etiology ALF, the rate of native liver recovery was also higher 
(67% vs. 33%, P=0.05) and the need for Ltx was significantly lower (13% 
vs. 50%, P=0.002) in the MARS treatment group. In the unknown etiology 
ALF subgroup, a similar tendency was noted towards higher native liver 
recovery (20% vs. 8%, P=0.294) in the MARS-treated patients. 
AOCLF
In the alcohol-related AOCLF group, two abstinent patients (4% of the entire 
group) received transplants. In the other-etiology AOCLF, nine patients out 
of 17 were transplanted.
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Re-transplantation in GF
In total, six GF patients underwent re-Ltx (4 early GF patients and 2 late 
GF patients).
Survival predicting factors 
According to the results from Study V, the etiology of liver failure was the 
most significant factor predicting survival (P<0.0001) with the highest 
mortality observed in the alcohol-related AOCLF subgroup. In the subgroup 
analysis, the most significant predicting factor for survival in paracetamol-
related toxic ALF was the grade of HE (OR 0.345; 95% CI, 0.154-0.774; 
P=0.001) prior to treatment. In the non-paracetamol-related toxic etiology 
ALF, the prognostic factors were thrombin time, (TT%) (OR, 1.103; 95% 
CI, 1.000-1.217; P=0.049), and the grade of HE before treatment (OR 0.562; 
95% CI, 0.305-1.035; P=0.064). 
In the unknown etiology ALF, the  predicting factors were the coagulation 
factor V levels (OR, 1.052; 95% CI, 1.007-1.099; P=0.02) and alanine 
aminotransferase (ALT) plasma levels (OR, 1.001; 95% CI, 1.000-1.001; 
P=0.013). The mathematical formulae predicting a 6-month survival without 
Ltx in different ALF etiologies are summarized in Table 14.
Table 14. The survival predicting formulae in the 
different etiological ALF subgroups.
Paracetamol-related toxic ALF 
 )1/(1100 )064.1831,3( ∗−−× HEep  
Non-paracetamol-related  toxic ALF 
  )1/(1100 )577.0*098.0*120,1( HETTep −−−×  
Unknown etiology ALF 
 )1/(1100 )051,0*001,0*894,4( FVALTep −−×  
HE=grade of hepatic encephalopathy, TT%=trombin time, 
ALT= alanine aminotransferase, coagulation factor V
Hepatic encephalopathy and the neuroactive amino acids 
During the MARS treatment, the grade of HE was significantly decreased 
(or the worsening of HE was halted)  in most patients (I,II,IV,V) (Figure 
A Critical Evaluation Of The MARS Treatment In Finland66
8.). In Study V, including the 192 treatment cases, the mean grade of HE in 
all patients decreased significantly during the MARS treatment (the mean 
HE grade before MARS 1.8 vs. after MARS 1.4, P<0.001). The opposite 
occurred in the historical control ALF group and the grade of HE increased 
significantly (P=0.032) during SMT (II). Also, a number of the MARS-
treated ALF (4/19) patients with over 80% liver necrosis showed no signs 
of HE before Ltx (IV). 
Figure 8. The grade of encephalopathy before and after the MARS 
treatment in the different liver failure etiological subgroups.
 
 
   
Before MARS After MARS 
With the majority of measured amino acids, the plasma concentrations 
were comparable between the ALF and AOCLF patients before the MARS 
treatment was started (I). The plasma levels of  phenylalanine (P<0.05), 
methionine (P<0.05), glutamine (P<0.01), and histidine (P<0.001) and 
also ammonia (P<0.001) were higher in the patients with the HE grade 
≥1 when compared to non-encephalopathic patients. The Fischer’s ratio 
improved in all the encephalopathic patients with the MARS treatment. In 
all patients, regardless of the HE grade upon admission, the plasma levels 
of AAAs (tryptophane, tyrosine and phenylalanine) decreased significantly 
during the MARS treatment. In addition, in encephalopathic patients, the 
levels of methionine, glutamine and histidine decreased significantly during 
MARS (Figure 9.). 
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Figure 9. Neuroactive amino acids and the Fischer’s ratio according to the 
encephalopathy grade, before and after the MARS treatments in Study I.
Data is presented as median with standard error bars ( 95% C.I.). Fischer’s ratio = 
valine+isoleucine+leucine / phenylalanine+tyrosine
measured laboratory variables and toxin removal 
The median plasma concentration of most toxic metabolites (bilirubin, 
ammonia and creatinine) as well as some neuroactive amino acids, 
trombocytes, hemoglobin and liver enzymes were significantly reduced 
during the MARS treatments (I, II, III, V). The median coagulation factor 
levels remained unaffected throughout the MARS treatment. The changes 
in key laboratory variables during the MARS treatment are summarized 
in Table 15.
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Table 15. The changes in the laboratory variables in 188 
patients during the MARS treatment in Study V. 
Laboratory variable 
(normal range)
Before MARS After MARS P-value
Hemoglobin g/l (125-180) 104 (59-170) 95 (59-136) <0.001
Leucocytes x109 (3.3-8.2) 10.3 (1.0-41.0) 9.6 (1.3-45.7) 0.200
Platelets x109  (145-360) 120 (11-511) 77 (6-349) <0.001
Sodium  mmol/l (137-146) 135 (115-150) 134 (128-145) 0.103
Potassium mmol/l (3.3-4.9) 3.8 (2.0-5.6) 4.0 (2.9-6.4) <0.001
C-reactive protein g/l (<10) 15 (5-356) 25 (5-215) <0.001
Creatinine µmol/l (0-110) 110 (29-1318) 55 (17-585) <0.001
Urea mmol/l  (2.5-8.5) 8.8 (0.8-56.5) 2.5 (0.2-58) <0.001
NH4-ion µmol/l  (10-65) 74 (8-512) 55 (4-309) <0.001
Bilirubin µmol/l (2-20) 410 (4-909) 243 (6-570) <0.001
AST  U/l (<40) 313 (15-24360) 156 (13-87380) <0.001
ALT  U/l (<50) 303 (9-12500) 159 (5-25120) <0.001
γ-GT U/l (5-80) 110 (8-2385) 65 (5-1619) <0.001
 FV % (70-139) 44 (5-201) 44 (5-149) 0.053
AT3 %  (70-130) 34 (13-137) 32 (15-122) <0.001
TT % (70-130) 22 (6-139) 22 (6-113) 0.334
INR (0.7-1.1) 2.5 (0.9-9.9) 2.4 (1.0-10.0) 0.262
Albumin g/l (35-55) 25.0 (11.5-46.4) 27.3 (15.7-48.1) <0.001
All laboratory values are expressed as a median (range). NH4-ion = ammonium-
ion , AST = Aspartate aminotransferase, ALT = Alanine aminotransferase, γ-GT = 
gamma glutamyltransferase, FV = Coagulation factor V, AT3 = Antitrombin III, TT 
(%) = thrombin time (includes coagulation factors II, VII, X), INR=international 
normalized ratio
Health-related quality of life
The estimated mean HRQoL of all the MARS-treated and control ALF 
patients prior to treatment was very low when compared to the age and 
gender-standardized reference population of Finland[15] (0.30-0.27 vs. 0.92). 
The highest 15D scores and the mean QALY gains after treatment were 
observed in the ALF patients who did not have a contra-indication to Ltx 
and recovered without it (Figure 10.). The HRQoL of a surviving transplanted 
MARS patients was generally very good, although it was still somewhat 
lower than that of the age-standardized general population [15] (0.84 vs. 0.92). 
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Figure 10. The 15D scores of the MARS-treated patients 
before and 3 years after treatment in Study VI. 
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costs and cost-utility 
The costs of the MARS treatment in Finland: Currently the MARS machine 
and dialysis sets are manufactured by Gambro. One MARS treatment session 
costs 4,900€, including the wages of the essential nursing staff (HUCH service 
tariff catalog 2009). The cost of a treatment day in a liver ICU setting is 3,720€ 
(HUCH service tariff catalog 2009). In comparison, the price of a Ltx operation 
(either urgent or elective) is 48,000€ including both the donor and recipient 
operations (HUCH service tariff catalog 2009). However, substantial additional 
costs are associated with the Ltx procedure, as all patients require ICU and 
hospital treatment afterwards for a varying period of time (ranging from a 
few days to weeks).
Most of the liver disease-related direct medical costs incurred within 
the first year of the treatment (VI). The mean overall direct medical costs 
over 3.5 years in all patients were significantly lower in the MARS treatment 
group when compared to the controls (79,745€ vs. 105,820€). The costs of 
the transplanted and non-transplanted ALF patients in the MARS group 
and the control group are shown in Figure 11. 
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Figure 11. The mean overall direct medical costs over 3.5 years per 
patient in the MARS-treated and control ALF patients in Study VI.
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The cost-utility of the MARS treatment: The incremental cost of the 
standard medical treatment alone compared to the MARS was 10,928€, 
and the incremental number of the QALYs gained by the MARS was 0.66. 
In the sensitivity analysis, the MARS treatment remained the dominant 
treatment strategy even though the difference in the etiological distribution 
between the MARS and the historical control group was taken into account 
and adjusted for. Table 16 shows a summary of the survival, cost and QALY 
data of Study VI. 
Table 16. Summary of cost-utility data in Study VI
N = number of patients, 15D-score = measure of the health-related quality of life
side-effects 
No serious or fatal side-effects were noted during the MARS treatment of 
195 patients. The development of significant trombocytopenia (P<0.001) 
was recorded during the MARS treatment (Table 15.), but no fatal bleedings 
occurred. Minor bleeding complications have occurred, such as the catheter 
puncture site oozing and mucosal bleeding problems, causing adjustment 
in the anticoagulation regime. 
3 years survival Total costs, € Mean 15D-score
Treatment 
group N %
Mean, 
days N Mean Min Max N
Before 
treatment
At 3 years 
or death
MARS 90 78 866 31 79 745 11 961 370 573 90 0.30 0.70
Control 17 41 460 16 105 820 16 862 262 481 17 0.27 0.36
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DISCUSSION
The present thesis evaluated the impact and effectiveness of the MARS 
treatment in a comprehensive manner by incorporating both outcome 
(survival, native liver recovery and need for Ltx), clinical (HE, survival 
predicting factors), biochemical (effect on plasma amino-acids and laboratory 
variables), psychological (HRQoL studies), as well as the economic aspects 
(direct medical costs and cost-utility analysis) of the 195 MARS-treated 
patients in Finland. Previously, only a few small uncontrolled pilot studies 
have addressed this patient population in our country[154, 155, 180, 189].
the strengths and main findings of this thesis
The 195 patients in this thesis represent the largest MARS-treated patient 
population studied in a single center. Study II is also the first published 
controlled MARS study that investigates the survival and outcome of ALF 
patients. In addition, Study VI represents the first cost-utility and HRQoL 
study which has been conducted on the MARS-treated ALF patients. Despite 
the limited number of patients in this thesis, the 195 MARS-treated patients 
including a total of 120 ALF patients, represent a large patient population 
when considering the rarity and high mortality in ALF, the population base of 
Finland, and other previous MARS studies. Furthermore, the follow-up time 
which ranged from 6 months (II) up to 3 years in (VI), was exceptionally long 
when compared with most other previously published MARS studies[141, 231, 339]. 
The main findings of this thesis were that the outcome of the MARS-
treated ALF patients, in terms of 6 months survival, native liver recovery rate 
and need for Ltx, was better when compared to a historical control group 
(II). In MARS-treated AOCLF patients with end-stage cirrhosis, mortality 
was very high without Ltx (V). The MARS treatment was successfully 
used as a bridging treatment to Ltx (II-VI) and in some cases, it seemed 
to facilitate native liver recovery (II,III,V,VI). Some patients with critical 
ALF and massive liver necrosis requiring a high urgent Ltx also seemed 
to endure a prolonged waiting time to Ltx with the MARS treatment 
(IV). Encephalopathy was often alleviated with the MARS treatment (I-
V) and the percentage of ALF patients dying from tentorial herniation 
decreased significantly during the MARS treatment era when compared to 
historical controls (II). Moreover, the removal of toxic substances such as 
ammonia, bilirubin and neuroactive amino acids and an improvement in the 
amino acid profile of the patients was observed with the MARS treatment 
(I, II and V).  In cost-utility analysis, MARS treatment of ALF patients was 
less costly and more cost-efficient  (VI) than SMT alone.
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Outcome
ALF
One might speculate that implementation of the MARS treatment in Finland 
has led to a trend of improved 6-month survival in both non-transplanted 
(66% vs. 40%) and transplanted (94% vs. 77%) ALF patients when compared 
to the historical controls from our own unit. The 1-year survival rate of our 
transplanted MARS-treated ALF patients also compares favorably to the 
international and European Ltx registries and previous studies (91% vs. 62-
81%)[42, 107, 294, 303, 307, 352, 353]. The overall ALF patient survival rate (including 
both transplanted and non-transplanted patients)  in previous MARS studies 
has been reported at 50-79%[54, 246, 344, 393], which is similar to our 1-year 
overall survival rate of 74%. Substantially poorer survival (~15-30%) with 
the MARS treatment has also been reported by some centers with limited 
possibility to Ltx[200] and ALF with high grade HE[190].
Study II of this thesis is the largest and the first published controlled 
MARS study in the world investigating the outcome of ALF patients in terms 
of survival, native liver recovery and need for Ltx. Due to the rarity and 
high mortality in ALF, as well as the varying availability and waiting times 
of transplant organs, randomized trials are difficult to carry out. Therefore, 
only a few RCTs including more than 100 ALF patients have been published 
in the context of liver-assist devices[80, 250] and only one RCT concerning the 
MARS treatment of ALF patients has been published in an abstract form thus 
far[298]. In the yet published RCT study by Saliba et al., the randomization 
of patients was done after the listing for the high urgent Ltx and the results 
showed a trend of higher overall survival in the transplanted MARS-treated 
patients compared with the controls receiving SMT (85% vs. 76%, P=ns)
[298]. However, the patient population in this French study[298] was quite 
different from ours, as all the ALF patients in the French study were listed 
for Ltx and 75% of  the patients received a graft within 24h of listing. The 
mean waiting time for Ltx in the French study[298] was only 16.2h, meaning 
that the total number and duration of the MARS sessions which the patient 
received was also lower when compared to our patients. In our MARS-
treated high urgently listed ALF patients (IV), the median waiting time for 
a graft was 5 days and the range was from 1 to 11 days. It is important to 
note that the median waiting time for high urgent Ltx in the Scandinavian 
countries is much longer[47] than the 1-2 days which is typically observed in 
the Eurotransplant-area[42, 298], Canada[352], and in the U.S.[107, 204, 294]. In fact, 
the median waiting time for a high urgent Ltx in the Scandinavian countries 
varies between 1.7-6.6 days, depending on the recipient’s blood type[47]. Even 
though high urgent ALF patients have a priority for the first available organ 
within three days of listing in the Scandiatransplant area, only about 60% 
of the patients receive a graft within this time period[43]. 
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In Study II, the etiological factors causing ALF differed significantly 
between the MARS and the control group (P=0.002). The unknown etiology 
ALF, which represented the majority of patients in the control group, is 
known to carry a poor prognosis, and has a low tendency of native liver 
recovery[204]. In contrast, the toxic and especially the paracetamol-related 
ALF patients who dominated the MARS group carry a substantially better 
prognosis and tendency for native liver recovery[202-204, 258]. For this reason, 
the subgroup analysis were carried out to compare patients with the same 
etiology. 
In a subgroup of the unknown etiology ALF, 56% of our MARS patients 
were transplanted as compared to 62% in the control group and the native 
liver recovery rates were 20% and 8%, respectively. In contrast, a large multi-
center U.S. study reported a 51% transplantation rate and a 17% native liver 
recovery rate in the unknown etiology ALF[258]. The 28-day survival of all 
our MARS-treated unknown etiology patients was higher when compared 
to the U.S. study (78% vs. 64%)[258]. In Study II it is also noteworthy that the 
survival of the transplanted MARS-treated unknown etiology ALF patients 
was higher when compared to the transplanted controls (91% vs. 69%) 
even though statistical significance was not achieved (P=0.1). One previous 
study has reported 80% survival in the transplanted ALF patients with an 
unknown etiology[382]. 
In toxic etiology ALF, including both paracetamol and other drug-
induced cases, a significantly lower rate of Ltx (13% vs. 50%; P=0.002) and 
a higher tendency for native liver recovery (67% vs. 33%; P=0.05) were noted 
in the MARS-treated patients when compared to the historical controls 
(II, VI). However, in our material, the MARS-treated toxic etiology ALF 
patients were in a better clinical condition prior to their treatment (i.e. a 
lower median MELD score and a higher percentage of non-encephalopathic 
patients), which might partly explain the favorable outcome. In other MARS 
studies, the spontaneous recovery rates in the toxic ALF patients have been 
reported at 33-79%[190, 393]. In comparison to a recent U.S. study on non-
MARS-treated patients, the native liver recovery rate with MARS was higher 
in both paracetamol patients (81% vs. 65%), and in other drug-induced ALF 
patients (52% vs. 29%)[204]. 
In Finland, only three patients have been transplanted due to pure 
paracetamol-intoxication during the past 27 years (FLTR 30.6.2009). In 
general, paracetamol-related ALF is probably not as common in Finland as 
in the U.S. and the United Kingdom[31, 175, 202, 203]. In the near future, however, 
this might change, as according to the new legislation in Finland, the amount 
of paracetamol which can be freely purchased over the counter without 
prescription is now 15g/client/day, as opposed to the previous  6g/client/day. 
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AOCLF
The first MARS related articles[141, 231, 339] and a few subsequent studies[145, 344] 
reported  surprisingly high survival rates of 52-92% for the AOCLF patients. 
In addition, two RCTs have shown a survival benefit favoring the MARS 
treatment as compared to the SMT[141, 231]. Other studies on cirrhotic AOCLF 
patients without MARS treatment have reported substantially lower 1-year 
survival rates of ~20-30%[125, 214] and even lower survival rates in the presence 
of co-existing complications such as HRS I and SBP[116]. 
Despite the initial encouraging survival results in the MARS-treated 
AOCLF patients, the majority of the subsequent studies have reported much 
lower overall survival rates ranging from 0 to 30%, especially in the patients 
lacking the Ltx option[62, 63, 87, 231, 237, 246, 376]. Our results support the findings 
of these less enthusiastic survival observations as the 1-year survival of our 
non-transplanted AOCLF patients was only 18%.  
When interpreting the results from the initial MARS studies, one must 
bear in mind that firstly, the follow-up time in some studies was extremely 
short (30 days or in-hospital survival)[141, 231, 339] and secondly, patients with 
serious co-morbidities and AOCLF-associated complications (such as 
HRS I, GI bleeding or hemodynamic instability) were excluded from other 
studies[141, 145, 191, 320]. Furthermore, the RCTs presenting favorable results only 
contained a total of 20 MARS-treated patients[141, 231]. Even though most 
AOCLF patients in the aforementioned studies were not transplanted due to 
contra-indications, the lack of the Ltx option in some countries undoubtedly 
has a negative effect on the overall survival results[376]. 
A survival subgroup analysis (V) showed that for the alcohol-related 
AOCLF patients with end-stage cirrhosis who are not eligible for Ltx, 
the MARS treatment is futile in terms of prognosis. This is because the 6 
month survival of these patients was less than 10%. However, if the alcohol 
liver exhibited signs of residual regenerative capacity (e.g. steatosis and 
enlargement with milder forms of chronic changes), the MARS treatment 
seemed to be more beneficial, even in the absence of an Ltx option, as 
native liver recovery was theoretically possible. Other MARS studies on 
alcohol-related AOCLF have reported short-term survival of ~50% [144, 162]. In 
contrast, a recent study by Wolff et al. revealed comparable survival results 
to our data, presenting 21% out-of-hospital survival rates[388]. 
All of the previously discussed AOCLF studies clearly demonstrate that the 
patient selection and exclusion criteria for the MARS treatment are one of the 
key elements in determining the prognosis of a patient. When interpreting the 
results from Study V, one must keep in mind that the indications in AOCLF 
patients for the MARS treatment at our center necessitated the presence of 
two of the following criteria: hyperbilirubinemia (bilirubin>400umol/l), type 
1 HRS or progressive HE.  Most of the non-transplanted AOCLF patients in 
our study were in such poor clinical condition prior to treatment that they 
could only be temporarily sustained with MARS. In fact, the median survival 
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time of the non-transplanted non-surviving AOCLF patients was only 8 
days after the initiation of the MARS treatment. After albumin dialysis was 
discontinued, most patients succumbed quickly to new complications and 
died. Therefore, it seems that the only long term possibility for the survival 
of the AOCLF patients with end-stage cirrhosis is Ltx. In a clinical setting, 
these findings have changed the existing MARS treatment indications in 
Finland. For the  AOCLF patients with end-stage cirrhosis and no signs of 
regenerative capacity, the MARS treatment is only justified if the patient is 
eligible for Ltx and the MARS is used as a bridging treatment. 
GF
The overall survival rate in this subgroup was high (8/11). In early GF, 
63% of our MARS-treated patients survived 1-year, which is comparable to 
other small MARS studies reporting survival figures around 60%[122, 146, 248]. 
However, due to the small number of GF patients in our study and other 
reports, it is not possible to draw conclusions as to the efficacy of the MARS 
treatment in this patient sub-population. 
Prognostic factors
To our knowledge, the 195 MARS patients contained in this thesis represents 
the largest MARS  population investigated so far in a single center. It also 
contains the first study to analyze the prognostic factors in the MARS-
treated patients in the different liver failure etiological subgroups (V). When 
evaluating prognosis, the stratification of patients into distinct etiological 
subgroups is essential. Based on previous studies, it is known that the etiology 
of liver failure is one of the most important determinants of outcome[202, 204, 
252, 258] and this was also noted in our study (V). Previously, only one study 
has examined prognostic factors in MARS-treated patients[392]. The study 
by Yuan et al. contained a heterogeneous group of 50 miscellaneous liver 
failure patients who were MARS-treated before Ltx. The conclusion was 
that MARS treatment had favorably affected the known risk factors of early 
postoperative mortality (sequential organ failure (SOFA) score, creatinine, 
INR, tumor necrosis factor-α, and interleukin-10)[392].
Our results (V) as well as a previous study by O’Grady et al.[251]have shown 
that the grade of HE is a significant predictor of survival in toxic etiology 
ALF. Interestingly, in our MARS-treated patients, the grade of HE was not 
a significant prognostic factor in unknown etiology ALF. This finding is 
noteworthy since the most used transplantation criteria in non-paracetamol-
related ALF, the King’s college criteria[251], include the presence of HE as 
one of the listing criteria. 
In Study V, the coagulation variables were found to be significant predictors of 
survival in non-paracetamol-related and unknown-etiology ALF. Other studies on 
ALF patients have also proposed that prothrombin time[251] and factor V level[36, 
267] to be significant predictors of survival. The coagulation status of the patient 
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is a reflection of the synthetic capacity of the liver. For this reason, coagulation 
factor levels usually serve as accurate indicators of the severity of the liver damage 
and decreasing levels indicate poor prognosis[36, 123, 251, 267], as noted in our study.
The higher plasma level of the liver enzyme ALT was found to predict a 
better outcome in unknown etiology ALF. One explanation for this might be 
that necrotic liver cells do not produce enzymes. In fact, the simultaneous 
decrease in the ALT and factor V levels in unknown etiology patient are 
signs of the declining synthetic capacity of the remaining liver mass. As 
more liver tissue is destroyed, the regenerative capacity and the probability 
of transplantation-free survival diminish.
Other previously identified prognostic factors in ALF such as the early 
lactate[30], APACHE II scoring system[179, 198], alpha fetoprotein[308, 314], MELD-
score[186], ratio of coagulation factors VIII and V[267], serum Gc protein[201], 
serum phosphate levels[311] and liver size[322], were not analyzed in the study V. 
In Study V, survival predicting factors could not be found in other liver 
failure etiologies. The most probable explanation for this is that the remaining 
subgroups contained such a few patients that a statistical analysis was not 
able to identify the existing prognostic factors. Also, factors predicting 
survival could not be identified in alcohol-related AOCLF because most 
patients died within 6 months.
Hepatic encephalopathy and amino acids
The definition of ALF before the era of Ltx required the presence of HE[359]. 
However, times are changing as is the definition of ALF and few studies 
have already reported adult ALF patients without HE[47, 101, 107, 382]. In Finland, 
the initiation criteria for the MARS treatment in ALF do not necessitate 
the presence of HE if the patient has rapidly progressive liver damage 
(a deterioration of clinical condition or of the liver’s synthetic function 
despite the best possible SMT). Moreover, in some intoxication patients (e.g. 
Amanita phalloides poisoning or lethal dose of known hepatotoxin without 
antidote), MARS is started as soon as possible without waiting for HE or 
for liver failure to develop.
According to the results of the present study as well as of many other 
studies[54, 138, 141, 232, 320], the degree of HE decreased significantly during MARS 
treatment (I,II,V) whereas the grade of HE increased in the control group 
receiving SMT (II). Additionally, Study II showed that the percentage of 
ALF patients who died as a result of tentorial herniation was significantly 
lower in the MARS treatment group when compared to the controls (II). In 
fact, four high urgently transplanted MARS-treated ALF patients with over 
80% necrosis of the liver showed no signs of HE before Ltx (IV). This was 
exceptional considering that there were only a few or no viable hepatocytes 
in the explanted livers. It seems that by removing neurotoxic substances from 
the blood, the MARS therapy can prevent or delay the development of HE 
and brain edema in these critical patients. These are significant findings since 
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one of the leading causes of death in ALF patients is tentorial herniation 
caused by critical brain edema[352]. By reducing HE grade and thus, the risk 
of brain edema, the MARS-treated patients might have better chance of 
survival as noted in the Studies II,IV and V. 
The waiting time for a high urgent Ltx in the Scandinavian countries 
can sometimes be too long for a critically ill patient. According to one 
Scandinavian study before MARS was available, the high urgently listed ALF 
patients who received their Ltx within 1-3 days of listing had a significantly 
higher survival (77% vs. 48%) when compared to those with longer waiting 
time (4-10days)[43]. Another Scandinavian study demonstrated that high 
urgently listed ALF patients who were non-encephalopathic at the time of 
listing had a mortality of 65% if they were not transplanted[47]. In our study 
IV, the survival in the MARS treated ALF patients did not differ in 
relation to the Ltx waiting time. According to these observations, early 
aggressive MARS treatment of ALF patients might improve the prognosis 
of the listed patients by minimizing the risk of developing critical brain 
edema and herniation.  
Earlier studies on the patophysiological mechanisms of HE have reported 
elevated levels of neuroinhibitory and neurotoxic substances and their 
precursors in the plasma of encephalopathic liver failure patients[52, 113, 147, 
358, 29]. Our results (I) also showed that the concentration of phenylalanine, 
methionine, histidine and glutamine were significantly higher in patients 
with HE when compared to non-encephalopathic patients. 
It has been proposed that the favorable effect of the MARS treatment on 
HE might be due to the changes in the plasma amino acid profile[19, 209]. In 
agreement with previously published investigations[19, 209, 313], results from our 
Study I also demonstrated an improvement in both HE grade, and Fischer’s 
ratio during MARS treatment. The increase in the Fischer’s ratio was mainly 
due to the removal of AAAs. The concentration of other neurotoxic and 
neuroinhibitory amino acids (e.g. methionine and glutamine) also decreased 
during the MARS treatment, and this decrease was more pronounced in 
patients with higher HE grades (I). The observed favorable effect on the HE 
and amino acid profile during MARS treatment could be explained by the 
removal of the excess of  the neurotoxic amino acids by the MARS filters. 
On the other hand, it might also be attributable to improved liver function 
and thus, diminished toxin production or increased clearance.
Toxin removal
The observation that many albumin-bound and water-soluble toxic substances 
can be removed from patient’s blood with the MARS treatment[336-338, 344] was 
also noted in our patients. The median bilirubin level of our MARS-treated 
patients was significantly decreased by -41% which is comparable to other 
reports ranging from -21% to -52%[141, 191, 231, 320, 344]. In our patients, there was 
also a significant reduction in their liver enzyme levels during treatment, 
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which was more pronounced in the ALF patients compared to the AOCLF 
patients (II). However, the interpretation of this finding is somewhat difficult 
because high enzyme levels are usually seen in the initial stages of ALF, 
whereas decreasing levels can either indicate recovery or progression to 
massive liver necrosis. On the other hand, cirrhotic patients may have normal 
or only slightly elevated liver enzyme levels despite acute decompensation. It 
should be kept in mind, however, that the reduction in the level of bilirubin, 
liver enzymes and other toxins does not necessarily correlate with survival, 
and thus the efficacy of the MARS treatment cannot be judged on these 
surrogate parameters alone.
In general, the coagulation parameters (with the exception of platelet 
count) remained unaffected throughout the MARS treatment, which can be 
expected as the MARS treatment does not synthesize or remove coagulation 
factors. The decrease in platelet count and hemoglobin might  be partly 
caused by the direct mechanical sheer caused by the filters in the MARS 
machine [109]. However, in some of our MARS patients, the coagulation 
status improved during treatment, which might be a sign of recovering 
liver function.
The median reduction of ammonia was -26% during the MARS treatment 
in Study V, which is comparable to other reports[54, 62, 246, 344]. However, 
the removal of water soluble toxins (e.g. ammonia, creatinine and urea) 
is not related to albumin dialysis itself but rather to the hemodialysis or 
hemofiltration module attached to the MARS circuit. Furthermore, plasma 
electrolytes did not change significantly in our patients during the MARS 
treatment because of the vigilant surveillance, the regular blood controls 
and the prompt correction of abnormal values.    
To date, the amatoxin removal capacity of the MARS treatment has remained 
unknown in the Amanita phalloides intoxications. During the past 20 years, many 
extracorporeal detoxification methods have been researched in the hope of finding 
a new cure for Amanita mushroom poisonings. The most frequently used methods 
include plasmapheresis, hemodialysis, hemofiltration and hemoperfusion[11, 167, 168, 
332, 378]. Given that the α-amanitin molecule is a small oligopeptide (0,9kD) and 
not protein bound in plasma[115], it would seem that, in theory, it could be easily 
dialyzed. Surprisingly though, some studies have found that hemodialysis and 
hemoperfusion are ineffective in removing amatoxins from the circulation[184, 
238]. Taking into consideration the short plasma half-life of amatoxins[108], it 
seems plausible that the efficacy of the MARS treatment in Amanita phalloides 
intoxications observed in our patients  is not based on the removal of the amatoxins, 
but rather, is based on the removal of other toxic substances or some amatoxins 
metabolites which are yet unknown and have not been measured.
On a larger scale, we speculate that early MARS treatment in ALF is beneficial 
because it removes circulating endotoxins and other cytotoxic mediators from 
the patient’s blood. According to current knowledge, these accumulating toxic 
mediators (bilirubin, ammonia, lactate, bile acids, aromatic amino acids, fatty acids, 
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mercaptans, phenols and endogenous benzodiazepines, various cytokines, and 
NO) are responsible for the end-organ damage (e.g. HE, hemodynamic instability) 
in liver failure [319, 339] as well as being a part of the vicious cycle  inducing further 
hepatocyte injury. Perhaps the good 1-year survival rate (100%) of our Amanita 
intoxication, as well as of other ALF patients, is partly attributable to the early 
initiation of the MARS therapy. In this light, early aggressive MARS treatment of 
ALF seems advisable before the development of critical ALF and of irreversible 
end-organ damage .
Cost-utility and the health-related quality of life
From the perspective of the health care provider and society, it is important 
to determine which medical treatments are cost-efficient, effective and 
which provide as many high quality life-years as possible for the patient. 
These days, the fair allocation of existing financial resources is a demanding 
task, as costs and the number of patients are escalating and new expensive 
treatments are introduced. In the cost-utility analysis, the QALYs gained by a 
given treatment are used as the measuring units of efficacy. Thus, the QALYs 
and cost/QALY-ratios can be used to compare the different treatments in 
terms of length of life and quality of life[357]. Currently, there is no consensus 
as to how much a QALY gained can cost but a 50,000€ threshold has been 
suggested[350].
Study VI  is the first published work on the cost-utility and HRQoL of 
the MARS-treated ALF patients. According to the cost-utility analysis, the 
MARS treatment seemed to provide a less expensive and more cost-efficient 
treatment option when compared to SMT alone in ALF patients (VI). This 
was mostly due to the decreased number of Ltx and therefore costs when 
compared to the controls. On average, the overall treatment costs of liver-
failure patients in an ICU setting are considerable with or without MARS, 
due to the long ICU treatment periods and, in some cases, Ltx costs. In 
fact, any treatment which reduces the number of Ltx has a huge impact on 
the total costs. The sensitivity analysis of the cost-utility data showed that 
by increasing the percentage of transplanted patients in the MARS group 
up to 42% or higher, the expected costs of the MARS group would exceed 
those of the control group.  
In Study VI, the cost/QALY was considerably lower in the MARS treatment 
group compared to control group (53,845€/QALY vs. 106,958€/QALY) during 
3.5years. The incremental cost of SMT was 10,928€ when compared to the MARS 
treatment. Recent Finnish studies have evaluated the cost-utility of the ICU 
treatment of sepsis[172] and renal replacement therapy in acute renal failure[397]. 
The cost/QALY of these treatments was reported at 2,139€/QALY in sepsis and 
220,000€/QALY in acute renal failure. In comparison, the  cost/QALY of ICU 
treatment following cardiac arrest and cardiopulmonary resuscitation was 10,107€ 
in a German study[130], whereas the use of activated protein C in sepsis patients 
in an ICU setting cost 46,600$/QALY[218]. However, in the aforementioned QALY 
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studies, the number of QALYs gained by the treatment was assumed to last until 
the remaining lifetime of the patient. When evaluating the results of our Study 
VI, one must bear in mind that it dealt with a time window of 3.5-years, thus 
severely underestimating the QALYs gained during the remainder of the patients’ 
lives. Alternatively, the lifetime expected costs and outcomes could have been 
extrapolated but this would have necessitated further assumptions and resulted 
in greater uncertainty. To demonstrate this, the theoretical cost-utility of the 
MARS treatment in ALF patients was calculated assuming that the surviving 
patients had the same lifespan as an average Finnish person. The resulting cost/
QALY was 8,570€. 
Previous studies on critically ill ICU patients have reported long-lasting 
negative effects on HRQoL following treatment[92, 169]. However, in our 
HRQoL analysis, the MARS and ICU treatment did not seem to have a 
lasting negative impact on the HRQoL of the ALF patient unless they were 
transplanted. Furthermore, the average HRQoL of the MARS-treated and 
transplanted ALF patients was only slightly lower when compared to the 
age-matched reference population in Finland[15]. Yet, this slight decrease 
probably has very small clinical relevance. Similar results have been obtained 
from previous studies on transplanted patients[356, 394].
The analysis of  HRQoL and the cost-utility in ALF patients in Study VI 
is unique in the sense that all previous similar small studies have evaluated 
AOCLF patients only[137, 143-145]. In addition, most of these studies have been 
carried out by the same center in Germany and all patients with serious co-
morbidities, liver disease- related complications or Ltx have been excluded 
from the analysis[143-145].  
MARS treatment protocols
In Studies I-VI, the target duration for one MARS session in ALF was 22 
hours, but in reality, the median duration of one MARS session was 16.5 
hours according to Study V. This was mainly caused by the clotting of the 
dialysis filters which occurred even with an adequate anticoagulation regime 
and led to the premature cessation of the treatment in many cases. In our 
MARS-treated ALF patients, the median length of the treatment sessions 
were considerably longer when compared to most other MARS studies 
where the target has been only 6-8h sessions[95, 141, 144, 231, 258, 320, 393]. Another 
significant difference in the treatment protocol used at our center compared 
to other centers is that the MARS treatment was used continuously in the 
ALF patients instead of it being administered in intermittent treatments. 
The aforementioned differences in treatment protocol might explain our 
success with the MARS treatment in ALF patients. 
Studies on acute kidney failure patients have shown that high intensity 
and an early aggressive initiation of conventional renal replacement therapy 
have a favorable effect on patient outcome[286, 287, 305]. The same analogy might 
apply to the MARS patients, as albumin dialysis is always coupled with a 
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hemodialysis circuit. Furthermore, extended removal of albumin-bound 
and water-soluble toxins in long treatment sessions may have an added 
favorable effect on the outcome in ALF. Our clinical experience has also 
shown that once the MARS treatment is initiated, even the most unstable 
patients can endure prolonged periods of dialysis. Similarly, earlier studies 
have concluded that continuous renal replacement therapies are preferred 
in ALF, as they cause less fluctuation in hemodynamics and ICP than the 
intermittent therapy[76, 78].     
Safety considerations
A significant decrease in the platelet count was observed in our MARS-
treated patients, although no fatal bleedings occurred. These findings are 
similar to other published reports by various MARS centers describing mild 
trombocytopenia and few minor bleeding complications[4, 21, 54, 62, 104, 109, 191, 231, 
237, 360]. One study reported that even though platelet loss is observed during 
the MARS treatment, the function of the remaining tromobocytes remains 
intact[109]. In general, it is difficult to separate the possible complications due 
to the MARS treatment and those which are normally attributable to critically 
ill liver failure patients. In our patients, the MARS treatment appeared to 
be safe and only some minor bleeding complications occurred. However, 
intensive surveillance of the coagulation factors and the clinical signs of 
bleeding complications is essential to correctly adjust the anticoagulation 
therapy during the MARS treatment. 
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LIMITATIONS OF THIS THESIS
The major limitations of this thesis is the non-randomized nature of all of 
the Studies I-VI, and this reduces the scientific value of the results. Studies 
II and VI used historical control patients from the time prior to the MARS 
treatment. Although all patients received the same SMT at the same ICU, 
it is undeniable that some treatment and monitoring protocols (such as the 
HVPF and the invasive ICP monitoring) and patients referral patterns have 
changed over time. 
One significant factor complicating the comparison between the MARS 
treatment group and the historical controls was the unequal distribution of the 
ALF etiologies between the groups in Studies II and VI. The MARS treatment 
group contained more patients with paracetamol-related intoxications with 
a favorable prognosis, whereas the control group contained a larger share of 
unknown etiology patients with less potential to native liver recovery[175, 258]. 
This was compensated for by comparing only patients with similar etiology in 
Study II and by adjustments in the sensitivity analysis in Study VI. However, 
in Study II, this led to a rather small number of patients in each etiological 
subgroup, complicating the statistical analysis. As ALF is an extremely rare 
condition, to gather a sample of even a few hundred patients with a similar 
etiology would take many decades in Finland. 
The general applicability of these MARS treatment results in other 
scenarios may vary according to many significant factors contributing to 
the overall survival and management of the liver failure patients (e.g. the 
distribution of liver failure etiologies, availability of transplant organs, Ltx 
waiting times, transplant organ quality, and availability/quality of  ICU 
management). For example, in Asian countries, the majority of the patients 
have a viral origin of liver failure[149, 203]. Our material contained only few 
hepatitis patients and therefore our overall survival results do not necessarily 
apply to the Asian or other populations with different etiological background. 
In Study III, the presence of amatoxins in the blood or urine was not 
confirmed by a laboratory measurement. We do not have a test for the 
quantitative analysis of amatoxins in Finland because these intoxications 
are so rare. Therefore, complete certainty that all ten patients really had 
Amanita phalloides intoxication could not be reached even though typical 
clinical signs and history of eating white mushrooms strongly suggested it. 
One obvious source of the bias in the HRQoL Study VI was the difficulty 
in estimating the pre-treatment baseline HRQoL of patients. This is 
a commonly recognized problem in the HRQoL studies of critically ill 
ICU patients[172, 397]. Most liver failure patients are encephalopathic if not 
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unconscious, and thus cannot fill-out the HRQoL questionnaires. For this 
reason, the pre-treatment HRQoL was assessed retrospectively by an expert 
panel in Study VI. However, previous studies have demonstrated that the 
subjective feelings of a patient, such as their pain or HRQoL, are usually 
misjudged or underestimated by the attending doctors, treatment staff, or 
even by close relatives[100, 295, 330]. It is also important to remember that the 
time-window of our HRQoL study was only 3.5-years and this severely 
underestimates the QALYs to be gained over the remaining lifetime.  
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CLINICAL IMPLICATIONS OF THIS THESIS
The results from Studies I-VI suggest several clinical implications.
Firstly, based on these results, it seems that MARS treatment might 
improve survival in ALF, and especially in the unknown etiology patients 
with a poor prognosis when compared to SMT. In toxic etiology ALF, the 
MARS treatment seems to promote native liver recovery and thus a larger 
portion of the MARS treated patients recovered without Ltx when compared 
to SMT. The reduced need for Ltx in the MARS-treated ALF patients lead 
to higher cost-utility when compared with SMT. As demonstrated in our 
studies, the progression of encephalopathy was halted and the concentration 
of circulating neurototoxins (e.g. neurotoxic amino acids) was reduced with 
the MARS treatment. In the light of these findings, it would seem plausible 
to recommend the early initiation of the MARS treatment in ALF before 
the development of life-threatening complications (such as progressive 
encephalopathy).  
Secondly, a new definition of ALF should be adopted to also encompass 
those patients who do not develop encephalopathy when liver assist therapy is 
initiated early in the course of the disease. As Study IV clearly demonstrated, 
even patients with total or almost total necrosis of the liver, and thus evident 
ALF, can remain non-encephalopathic or improve their grade of HE  if 
treated continuously with MARS.
Thirdly, in those AOCLF patients with end-stage cirrhosis who are not 
eligible for Ltx, the MARS treatment is not meaningful in terms of prognosis. 
Therefore, the results from Study V suggest that in the future, the treatment 
of AOCLF patients be restricted to situations where the patient can either 
be bridged to Ltx or the liver still shows some signs of residual regenerative 
capacity (e.g. alcohol hepatitis with an enlarged steatotic liver with minor 
chronic changes).
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ETHICAL CONSIDERATIONS
As discussed earlier, the efficacy and survival benefit of the MARS treatment 
has not been substantiated with large RCTs. Most evidence supporting the 
beneficial effects of the MARS treatment originate from a few RCTs with 
AOCLF patients[138, 141, 191, 231, 320, 333, 335] and  uncontrolled case series[54, 344] 
with a limited number of patients and a short follow-up. It has always been 
difficult, if not impossible, to conduct RCTs in patients with a life-threatening 
medical condition. Consequently, in these circumstances, large case series 
must serve as a justified means of gathering information for a lack of a better 
option, especially when it comes to ALF patients. So far, only two RCTs[80, 
250] and one abstract[298]  have been published containing more than 50 ALF 
patients. In these days, a study design with randomization to either SMT 
or the MARS treatment without a rescue Ltx option, would not be possible 
due to ethical considerations. 
From point of view of society, the MARS treatment is a costly procedure 
which can only be applied to a carefully selected, small group of patients 
and therefore it has no great impact on the medical welfare of the entire 
population. On the other hand, the possible benefits of the MARS treatment 
can be of great consequence to an individual patient if a Ltx can be avoided 
or if the patient can be kept alive while waiting for a suitable transplant. 
All studies in this thesis (I-VI) complied with the current ethical 
considerations and are in accord with the Declaration of Helsinki. In 
addition, the collection and analysis of this patient material was assessed 
and approved by the ethical committee of Helsinki University Hospital.
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FUTURE  OF THE MARS TREATMENT
In recent years, the usefulness, efficiency and survival benefit of liver assist 
devices, including the MARS treatment, have been discussed in many reviews 
and editorials[57, 81, 124, 188, 192, 226, 233, 256, 268, 280, 290, 299, 334, 383, 386]. All the papers have 
more or less arrived at the same conclusion that the current liver support 
devices have shown somewhat promising results, especially in improving 
the clinical variables such as the HE and hemodynamic profile in addition 
to a significant ability to remove toxins from the blood. However, as these 
surrogate endpoints do not directly correlate with survival or with other 
clinically important endpoints such as native liver recovery or the need for 
a Ltx, large RCTs with hard endpoints are needed. 
Today, as randomized controlled and sufficiently powered studies on 
liver assist devices and MARS treatment are still scarce, definite conclusions 
cannot be drawn as to the survival benefit of these devices. A Cochrane 
review[208] evaluating the beneficial and harmful effects of the artificial and 
bioartificial liver devices stated that there is not enough supporting evidence 
that either BAL or artificial liver support systems have a significant effect 
on the outcome in ALF when compared to a SMT. However, according to 
this review, artificial liver support systems might be beneficial in AOCLF 
patients by reducing mortality and HE[208]. This review included only those 
studies which had been published until 2002. Future randomized controlled 
MARS trials are needed to demonstrate if the MARS treatment improves 
long-term survival. 
As the indications for the MARS treatment have been expanding during 
the past decade, it is essential to determine which patient groups genuinely 
gain from it. A sufficiently large sample size for an adequately powered 
clinical trial could only be achieved with a multinational multi-center study 
with substantial financial resources. Other important questions which 
remain unanswered concern the optimal length of the MARS treatment 
session (continuous vs. intermittent treatment) and the optimal timing of 
treatment in the different liver failure etiologies 
the liver assist device of the future
The development process towards the ultimate liver assist device, which 
could compensate for all the functions of a normal healthy liver, is far from 
over. An ideal liver support device would perform a wide range metabolic, 
synthetic and detoxification functions in addition to being reasonably priced, 
safe and easy to use in clinical practice.
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The future hope rests on the continuous research on the hybrid liver 
assist device technology which combines the efficient toxin removal capacity 
of the MARS system and the synthetic capacity of the BAL devices. In the 
meanwhile, the MARS treatment seems to provide a possibility for temporary 
liver support until the patient’s own liver regenerates or a suitable transplant 
organ is found.
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CONCLUSIONS
No serious adverse side-effects or complications were observed during the 
MARS treatment of 195 patients. 
Based on Studies I-VI, the major conclusions are: 
1. The 1- and 3-years survival and the rate of native liver recovery were 
higher and the need for Ltx was lower in the MARS-treated ALF patients 
when compared to historical controls. As the etiological distribution 
of patients has changed markedly over the past decade, the outcome 
of these groups cannot be compared directly. In subgroup analysis, the 
results suggested a survival benefit in especially MARS-treated unknown 
etiology ALF patients when compared to historical controls.
The survival of transplanted MARS patients was high and the patients 
who were bridged to Ltx gained from the MARS treatment independent 
of liver failure etiology. The AOCLF patients with end-stage cirrhosis 
and hyperbilirubinemia, HE or HRS, did not benefit from the MARS 
treatment if Ltx was contra-indicated. In AOCLF, if the liver was still 
enlarged and steatotic owing some regenerative capacity, the MARS 
treatment was more beneficial even in the absence of the Ltx option.
2. The most important predictor of survival was the etiology of liver failure. 
Other survival predicting factors were the grade of HE in the toxic 
etiology ALF and the plasma concentration of the coagulation factors 
and the liver enzyme ALT in unknown etiology ALF. In other liver failure 
etiologies this study was unable to detect survival predicting factors. 
3. A favorable effect on the plasma amino acid profile, removal of neurotoxic 
amino acids and improvement in the Fischer’s ratio was noted during 
the MARS treatment in both the ALF and AOCLF patients. The plasma 
concentration of most neuroactive amino acids, such as the  aromatic 
amino acids and glutamine, decreased significantly during treatment. 
The grade of HE decreased in most liver failure etiological subgroups 
or remained unchanged during the MARS treatment Also, the number 
of patients who died due to tentotorial herniation was significantly lower 
in the MARS treatment group when compared to the historical controls. 
According to the results of this study, the early MARS treatment of ALF 
patients might improve prognosis by removing the neurotoxic substances 
from the blood and thereby decreasing the risk of critical brain edema 
and herniation.  
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4. The concentration of all measured albumin-bound (e.g. bilirubin) and 
water-soluble toxins (e.g. creatinine, urea and ammonia) decreased 
significantly during the MARS treatment while the coagulation factors 
remained unaffected or increased in some patients. The platelet count 
was also significantly reduced during treatment but did not cause any 
fatal bleeding complications.
5. In an ICU setting, the MARS treatment combined with SMT appears to 
be less costly and more cost-efficient than SMT alone in ALF patients. 
This was mainly caused by the decreased number of Ltx in the MARS 
group when compared to the historical controls. 
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